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Jeff R. Gehlhausen 
 
PHENOTYPIC AND MOLECULAR CHARACTERIZATION OF A NOVEL 
MOUSE MODEL OF NEUROFIBROMATOSIS TYPE 2 
 
Neurofibromatosis Type 2 is a genetic disease that predisoposes patients to the 
development of multiple benign nervous system tumors, the most common being 
schwannoma.  To date, there are no mainstream medical alternatives to surgical 
excision for these tumors, which has the potential to increase disease burden.  
To better study NF2 disease, we generated a conditional knockout mouse that 
excises the Nf2 gene in the developing Schwann cell lineages.  Phenotypically, 
this mouse recapitulates important aspects of human NF2 disease, including 
complete schwannoma penetrance and hearing loss that correlates with 
vestibular schwannoma development.  
 
In parallel studies, we analyzed genomics data comparing human schwannomas 
and normal nerve tissue for deregulated signaling pathways that may be involved 
in schwannoma genesis.  Our investigation suggested that the NF-κB signaling 
pathway is activated in schwannoma tumors.  The NF-κB pathway is known to 
regulate cellular proliferation and survival, and has been implicated as the driver 
of other cancers, including ependymomas, which also frequently arise in NF2 
patients.  We validated these findings in our NF2 mouse model by demonstrating  
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increased nuclear accumulation of NF-κB transcription factors in schwannomas 
with a concomitant increase in NF-κB target gene expression.  Analysis of human 
and mouse tumors for upstream kinases regulating NF-κB transcription factor 
localization revealed a fragment of the kinase domain of NIK, a potent oncogene 
in the NF KappaB signaling pathway. Transduction of primary Schwann cells with 
this NIK kinase fragment increased proliferation, survival, and adhesion, while 
also inducing a gene expression profile highly reminiscent of that observed in 
both human and mouse schwannoma.  Altogether, these studies demonstrate 
the remarkable ability of a phenotypically accurate genetic murine model to 
provide molecular insights into human disease.  
 
D. Wade Clapp, M.D., Chair 
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INTRODUCTION TO CHAPTER ONE 
 
Neurofibromatosis Type 2 
Neurofibromatosis type 2 (NF2) is an autosomal dominant disorder that arises 
from germline heterozygosity of the NF2 tumor suppressor gene located on the 
long arm of chromosome 22.  Affected individuals have a high propensity for the 
acquisition of multiple tumors of the nervous sytem, especially schwannomas.  
NF2 disease is observed at a frequency of roughly 1 in 25,000 individuals [1].  
Phenotypically, NF2 is known to demonstrate variable expressivity, but it is 
almost fully penetrant by the age of 60 [2, 3]. 
 
NF2 patients are predisposed to develop benign lesions of the skin, eyes, and 
nervous system.  Bilaterial vestibular schwannomas (VS) are pathognomonic for 
NF2 disease, with up to 95% of patients acquiring these tumors.  These tumors 
are referred to as VS because they grow on cranial nerve VIII (CN VIII), the 
vestibulocochlear nerve.  This is the nerve that mediates both the sense of 
hearing and balance from structures in the inner ear.  Most patients also develop 
multiple schwannomas in the cranial, spinal, and peripheral nerves [4-14].  
Schwannomas are also the most common peripheral nerve tumor in non-NF2 
patients and are almost universally NF2-deficient, underscoring the critical 
function of this tumor suppressor in the Schwann cell lineage [1].  Other tumors 
often seen in NF2 patients include intracranial meningioma (up to 58%) and 
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spinal cord ependymoma (up to 53%).  Cutaneous tumors, typically 
schwannomas, are seen in up to 68% of patients [15, 16].  Cataracts and/or 
hamartomatous lesions of the eye are also common findings, present in up to 
81% of patients.   
 
Despite the fact that NF2 is a genetic disease, the diagnosis of patients remains 
one based on clinical criteria, and the presence of a germline NF2 mutation is not 
required.  The most popular tool used to diagnose patients, the Manchester 
criteria [17], primarily uses the knowledge that an individual has a known family 
history of NF2 or bilaterial vestibular schwannomas along with other NF2-related 
manifestations.  The wide acceptance of these criteria is largely based on its 
sensitivity, as well as ability to diagnose patients with no family history of NF2, 
which occurs in more than half of patients [18].  
 
Individuals afflicted with NF2 typically present as young adults with hearing loss 
resulting from a VS.  Frequently, hearing loss is only on one side, and can be 
accompanied by vestibular symptoms including tinnitus (“ringing of the ears”), 
dizziness, and loss of normal balance [4, 5].  Interestingly, children often present 
with a different constellation of symptoms, including visual abnormalities 
(resulting from eye lesions or intracranial tumors), cutaneous tumors, spinal cord 
tumors, and mononeuropathy [19-21]. 
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The first account of a patient with NF2 was in 1822, with the physician describing 
a deaf patient with multiple tumors in the skull, dura, and brain [22].  The disease 
was identified as having an autosomal dominant mode of transmission after 
following two families with NF2 manifestations, including VS, through multiple 
generations [23, 24].  NF2 was frequently confused with Neurofibromatosis Type 
1, another autosomal dominant disease predisposing patients to tumors of the 
nervous system, until linkage analysis studies demonstrated these diseases to 
be genetically distinct [25, 26].   
 
NF2 disease course and severity is frequently similar within families but can differ 
substantially between families, suggestive of a genotype-phenotype association 
[1].  More detailed genetic studies revealed this phenomenon to be true, with 
germline nonsense or frameshift mutations resulting in more severe disease 
when compared to those harboring missense mutations [27, 28].  Splice-site 
mutations can lead to variable disease phenotypes, but it has been noted that 
mutations affecting exons 1-5 of NF2 result in increased disease severity than 
mutations in exons 11-15 [29]. The genotype-phenotype association is also 
observed with risk of mortality, as patients with more severe mutations end up 
with an increased disease burden including more spinal and peripheral nerve 
tumors, intracranial meningiomas, and cataracts [30].  Overall, NF2 patients do 
suffer from early mortality, but they also face substantial morbidities, as most 
become deaf and many will require wheelchair assistance.   
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VS are the chief source of morbidity for NF2 patients.  They can also contribute 
to early mortality due to brainstem compression and surgical complications [1, 
31].  Early surgical intervention in VS can preserve some degree of CN VII and 
CN VIII function, though the decision of when to intervene can be challenging 
[32].  Much of the difficulty comes from the knowledge that there appears to be 
little to no correlation between tumor size and hearing loss [33].  Further 
confounding the issue is that VS are known to have highly variable rates of 
growth [1].  Some clinicians may wait to intervene surgically until deterioration in 
hearing is noted, but operative morbidities increase with tumor size [1].  Surgical 
resection also remains the treatment of choice for symptomatic spinal 
schwannomas.  Overall, this is a very challenging disease to manage surgically, 
as the surgeries inevitably take place in and around critical anatomical structures 
of the nervous system.  With this in mind, compromised or total loss of nerve 
function after surgical intervention is not an unusual event. 
 
Histopathological examination of human schwannomas reveals a few hallmark 
features that distinguish them from other tumors of the nervous system.  They 
tend to demonstrate a biphasic growth pattern, with some regions displaying a 
dense arrangement of spindle-shapped schwannoma cells (“Antoni A”), and 
other regions appearing to be largely acellular (“Antoni B”).  Verocay bodies are 
also observed, which are seen as with rows of tumor cells (nuclear palisades) 
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separated by acellular regions.  Nuclear pleomorphism may also be observed.  
Schwannomas are found to be uniformly positive for the neural crest marker 
S100 [34]. 
 
NF2 molecular biology 
NF2 is a 595 amino acid protein encoded by 17 exons.  Two isoforms, I and II, 
exist in humans and are the result of alternative splicing.  Isoform I includes exon 
17 with exon 16 spliced out, while Isoform II includes exon 16 but not exon 17.  
There are conflicting data on which isoform predominantly functions as a tumor 
suppressor, as evidence has been found for both isoforms [35, 36].  NF2 is a 
member of the ERM family of proteins, where ERM stands for Ezrin, Radixin, and 
Moesin.  Ezrin, Radixin, and Moexin are the canonical proteins of the ERM 
family, with an amino-terminal FERM domain followed by a coiled-coil domain 
and a C-terminal hyprohilic region [37, 38].  Though NF2 has the same 
organization of the ERM proteins, it also has distinct sequence motifs as well [38, 
39].  Two major differences in NF2 when compared to other ERM proteins is the 
lack of a C-terminal actin-binding motif, as well as the inclusion of a seven 
amino-acid (AA) Blue-box motif in the FERM domain that is evolutionarily 
conserved.   
 
ERM proteins are held in an inactivated state by an association between the C-
terminus and FERM domain, and in response to activation by Rho kinases, a C-
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terminal residue of the ERM protein is phosphorylated.  This phosphorylation 
disrupts the closed FERM domain-C-terminal association, opening the ERM 
protein for interactions with binding partners.  In their open configuration, ERM 
proteins bind the cytoplasmic regions of cell-adhesion receptors like CD44 and 
ICAM through their FERM domain.  They are also free to bind actin filaments 
through their C-terminal actin-binding domains.  Through these molecular 
interactions, ERM proteins function as regulators of the cell cytoskeleton [40-43].   
 
NF2 has also been shown to be regulated in a similar fashion to other ERM 
proteins, switching from a closed, tumor-supressive form to an inactive, open 
configuration in response to phosphorylation at Serine 518 by P21-activated 
kinase (PAK1) [44].  Support of this relationship is seen through site-mutant 
studies, with mutation of Serine 518 to Alanine increasing the inhibitory function 
of NF2, while mutation to an Aspartic Acid abolishes NF2’s tumor suppressive 
function [45-47].  Deletion of the Blue Box motif in NF2 is sufficient to induce 
dominant-negative behaviour, as overexpression of this mutant promotes cellular 
transformation in-vitro [48].  Additional evidence of the importance of this motif is 
seen in Drosophila, where overexpression of a Blue box deletion mutant causes 
excessive wing proliferation [49].   
 
In response to various anti-mitogenic signals, such as growth factor starvation, 
contact inhibition, and loss of cell adhesion to the ECM, the dephosphorylated, 
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tumor suppressive form of NF2 is increased [50].  Activation of Integrin or 
receptor tyrosine kinase (RTK) signalling leads to activation of CDC42/Rac1, 
which are well-established activators of PAK1.  Activated PAK1 then 
phosphorylates NF2 at S518, inactivating its tumor suppressive function [51, 52].  
NF2 also exerts a negative regulatory function on PAK1, preventing it from being 
activated by upstream Rac singaling through binding to the P21-binding domain 
of PAK [53].  Overall, the molecular interplay present in the Rac-PAK-NF2 axis 
has been suggested to resemble a feed-forward inactivation loop, whereby Rac 
activates PAK1, which inactivates NF2, freeing PAK to promote downstream 
signalling [51-53].   
 
In the context of contact inhibition of cell proliferation, homophilic cadherin 
interactions lead to inactivation of PAK1, resulting in an increase of the closed, 
tumor-supressive form of NF2 [50].  Considering NF2 is an ERM family member 
with prevalant cortical localization, it has been suggested that NF2 exerts its 
function as a tumor suppressor by regulating molecular events at the cell 
membrane.  Support of this relationship is seen in NF2-deficient cells, which do 
not arrest in the cell cycle at confluency as do normal, contact-inhibited cells [51]. 
The localization of NF2 in confluent cell states also supports this hypothesis, as it 
has been observed to accumulate to cell-cell contacts in epithelial cell types at 
confluency in cell culture [51, 54].  Another study identified NF2 to accumulation 
and interaction with a protein complex at the tight junction in epithelial cells [55].   
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NF2 is also an inhibitor of mTORC1 signalling, a fundamental pathway known to 
control protein translation [56, 57].  mTORC1 activation increases cell 
proliferation and survival through phosphorylation and inhibition of two 
downstream targets, p70-S6K1 and 4E-BP1.  In response to activation by 
integrin signalling, PAK1 phosphorylates and inactivates NF2, leading to an 
increase in downstream mTORC1 activation.  A schematic of the relationship 
between Rac, PAK, NF2, and mTORC1 is seen in Figure 1. Support for this 
relationship is seen in constitutive activation of mTORC1 in NF2-deficient 
mesothelioma, meningnioma, and vestibular schwannoma cell lines.  This 
activation appears to be independent of two well-established upstream regulators 
of mTORC1, AKT and ERK [57].  NF2-deficient mesothelioma cell lines are more 
sensitive to mTORC1 inhibition by Rapamycin than NF2-competent 
mesothelioma cell lines, which suggests an important role for mTORC1 signaling 
in NF2-deficient tumors [56].  
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Figure 1. Schematic representation of Rac-PAK-NF2 signaling axis.  In 
response to stimulation through activated RTKs or Integrin signaling, Rac’s 
activated GTP-bound form is recruited to the cell cortex where it promotes PAK1 
autophosphorylation and activation.  Once activated, PAK1 phosphorylates NF2 
at Serine 518, resulting in its inactivation.  The inactivation of NF2 results in 
constitutive activation of mTORC1, which increases ribosomal biogenesis and 
protein translation.  The net effect of mTORC1 activation is an increase in cell 
survival and proliferation, amongst other changes in cell function and behavior. 
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The Schwann cell lineage 
Schwann cells are a neural crest-derived glial cell population and the primary 
glial cell found in peripheral nerves.  They differ from oligodendrocytes, the 
myelinating CNS glial cell population, in that Schwann cells form myelin around 
single axons only.  Developmentally, there are three different embryonic 
Schwann cell stages.  The first stage includes neural crest cells, which gives rise 
to Schwann cell precursors (SCP, present from Embryonic day 12-13 in mice), 
and finally to Immature Schwann cells (present  from Embryonic day 13-15 in 
mice) [58, 59].  These cell types are transient, and their ultimate fate as a 
myelinating or non-myelinating Schwann cells depends on the caliber of the axon 
they associate with.  Myelinating Schwann cells are found in association with 
large caliber axons, whereas non-myelinating Schwann cells are found with small 
diameter axons [60]. 
 
Many different signals have been identified as important for the progression of 
glial cells from neural crest cells into a mature, myelinating phenotype [60].  
SOX10, a transcription factor, is required for the development of all peripheral 
glial cells [61].  NRG1, a ligand for the ErbB family of receptors, is essential for 
SCP survival [59, 62].  Autocrine signalling is critical for Immature Schwann cells, 
especially signalling derived from NRG1-ErbB family of receptors and Laminin-β1 
Integrin interactions [63-66].  Promotion from immature Schwann cells into a 
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myelinating phenotype involves the integration of many different signals, 
including those from NF-κB, Krox20, and OCT6 [67-70].   
 
Mouse models of NF2 
A useful preclinical animal model of human disease requires broad physiological 
relevance at both genotypic and phenotypic levels [71]. Therefore, genetically 
engineered murine (GEM) models of human disease should harbor mutations in 
gene(s) homologous to gene(s) mutated in human cancer. Moreover, this genetic 
perturbation should occur in cell types and gene doses similar to the hypothetical 
human tumor cell of origin. These tissue-specific genetic mutations should induce 
tumors that share histological and biological characteristics with the 
corresponding human tumors. Additionally, the GEM tumors should be expected 
to develop in a similar anatomical distribution and with similar functional 
consequence as human tumors. Since loss of Nf2 expression results in 
embryonic lethality in mice and Nf2+/- mice do not have a Schwann cell 
phenotype, conditional knockout technologies must be employed for the 
generation of NF2 mouse models [72, 73].  Importantly, the first generation 
murine NF2 model demonstrated that Nf2 disruption in Schwann cell lineages 
during embryogenesis promotes schwannoma formation [74, 75]. In existing 
models, however, schwannomas are incompletely penetrant (only occurring in 
about one-third of mice), and, generally, arise only late in life. Furthermore, 
vestibular schwannomas have not been observed in existing murine models of 
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NF2. These temporal, anatomical, and functional divergences from the human 
phenotype are critical barriers to in vivo genetic and pharmacologic studies that 
could facilitate better understanding of the molecular pathogenesis of NF2-
associated schwannomas. Additionally, lack of an optimal mouse model NF2-
associated schwannomas prevents the development and preclinical testing of 
novel therapeutics for these tumors.   
 
The prior published murine Nf2 conditional knockout model depends on Cre-
mediated Nf2 allele excision driven by the P0 promoter element, which is 
expressed in neural crest cells at embryonic day 9.5 (E9.5) and in SCPs at E12.5 
[75]. We hypothesized that an alternate promoter element with distinct 
developmental timing and anatomical distribution may provide an additional 
opportunity to recapitulate the phenotypic consequences of human NF2 
mutations and disease manifestations in mice. Therefore, we investigated Cre 
expression driven by the 3.9kb upstream promoter region of the Periostin gene 
(Postn-Cre), which prior studies have shown to drive robust reporter gene 
expression in Schwann cell progenitors beginning at E10 [76]. We intercrossed 
mice carrying loxp sequences flanking exon 2 of the Nf2 gene (Nf2flox/flox) [75]  
with Postn-Cre mice, generating Postn-Cre; Nf2flox/flox mice and their Cre-negative 
control littermates. Here, we present this intercross, which results in the 
consistent development of schwannomas that closely recapitulate features of the 
human disease, including hearing loss and vestibular impairment associated with 
vestibular schwannoma development.  
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MATERIALS AND METHODS 
 
Study approval 
All studies were carried out in accordance with, and approval of, the Institutional 
Animal Care and Use Committee (IACUC) of Indiana University Medical School, 
the U.S. Department of Agriculture’s (USDA) Animal Welfare Act (9 CFR Parts 1, 
2, and 3) and the Guide for the Care and Use of Laboratory Animals.  
 
Statistical methods 
Statistical analyses were performed with GraphPad Prism 5.0. The Kaplan-Meier 
method was used to analyze the survival outcomes of mice, and the Log Rank 
(Mantel-Cox) test was used to compare survival curves. As noted in the text, 
Analysis of Variance (ANOVA) with Bonferonni post-hoc analysis or Student’s T-
test was used to test for differences in tumor volume and hearing threshold. 
Specific tests and significance levels can be found in the figures and figure 
legends. Fischer’s Exact test for Independence was performed on the vestibular 
phenotypic data using the R Statistical Programming Environment. P values less 
than .05 were considered significant.   
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Hearing screening 
Auditory brainstem responses (ABRs) were recorded from left and right ears of 
anesthetized mice (100 mg/kg ketamine and 10 mg/kg xylazine by intraperitoneal 
injection) using subdermal needle electrodes. Stimuli were produced and 
responses were recorded with a Tucker-Davis Technologies (TDT) BioSigRZ 
system, using a RZ6 digital/analog converter (TDT). Responses to clicks (512 
repetitions, 30-90 dB SPL in 10 dB steps, presented at 21/s with a closed-field 
system) were amplified, filtered (3 Hz - 3 kHz), averaged, and stored for offline 
analysis in Matlab (Mathworks, Natick, MA). ABR waveforms were additionally 
high-pass filtered (cutoff 200 Hz) to remove slow oscillations and emphasize 
characteristic ABR peaks. ABR threshold was defined as the lowest measured 
SPL at which a reproducible peak or trough was identified. Amplitude of the 
summating potential (SP) was calculated as baseline-to-peak, and amplitude of 
wave 1 (W1) was calculated as peak-to-trough. 
 
Mice and genotyping 
Postn-Cre and Nf2flox/flox transgenic lines were maintained on Teklad Lab Animal 
Diet (TD 2014, Harlan Laboratories USA) using a 12:12 (light/dark) photoperiod 
at 22-24 degrees Celsius. Nf2flox2 and Nf2∆2 bands were detected by PCR 
Analysis as described in Giovannini et al., Genes and Dev., 2000. The Postn-Cre 
transgene was detected by PCR analysis with the following primers: P1 (CAT-
TTG-GGC-CAG-CTA-AAC-AT) and P2 (CCC-GGC-AAA-ACA-GGT-AGT-TA). 
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Band sizes are reported in Figure 10. Postn-Cre; Nf2flox/flox mice and Cre-
negative controls possessed the same mixed genetic background, with SNP 
analysis indicating close relation to the FVB/NTac strain (87.37% identity). 
 
Histology and immunohistochemistry  
Tumors were excised from recently sacrificed animals, fixed with 10% formalin, 
embedded in paraffin, sectioned, and stained with H&E. Embryos were fixed in 
4% Paraformaldehyde (PFA), stained with X-gal, embedded in paraffin, and then 
sectioned. Vector labs ABC (PK-6100), DAB (SK-4100), and Avidin/Biotin 
blocking (SP-2001) kits were used for immunoperoxidase staining. BLBP 
(Abcam, ab32423) primary antibody was detected with biotinylated Goat anti-
Rabbit secondary antibody from Sigma (cat. B8896). For sectioning and staining 
of inner ear structures, mice were fixed with 4% PFA injected via intracardiac 
perfusion into the right atrium. Samples were then sent to Dr. Brian Faddis at the 
Otolaryngology Histology Core at Washington University in St. Louis for 
processing and staining.  
 
Tumor volume quantitation 
After fixation and decalcification in 5% formic acid, the DRG and spinal nerves 
were then dissected out under a microscope. Tumor volume was calculated 
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using the length and width values for a particular tumor in the formula volume = 
length x width2 x .52, the approximate volume of a spheroid. 
 
Vestibular studies 
All of the functional vestibular studies (trunk curl, contact righting, and swim) 
were performed on three consecutive days, with each test being performed once 
per day. The tests were scored by two independent observers experimentally 
blinded to the genotype of each animal. Fischer’s Exact test was used to test for 
differences in the two genotypes. 
 
For the trunk curl test, mice were individually suspended by their tails and 
presented with a horizontal platform roughly 2 cm outside their reach. Control 
mice will reach toward this platform, but mice with vestibular impairment will tend 
to curl in toward their abdomen with their head and upper-body. This inward-
curling was scored as a failure for the test. Mice were scored on a two-point 
system, either succeeding or failing the test. 
 
In the contact righting test, mice were placed in a 45 cm Plexiglas tube with a 
diameter of 6 cm, and the tube was re-oriented until the mouse was at the 
approximate center of the tube, facing toward the closed end. The tube was then 
rotated and the ability of the mice to correct their posture was assessed. Mice 
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that had significant difficulty adjusting to the rotation fell on their sides or on their 
backs. This was scored as a failure of the test. Mice were scored on a two-point 
system, either succeeding or failing the test. 
 
For the swim test, a large sink (50 cm x 40 cm x 20 cm) was filled with tepid 
water to a depth of 18 cm and given several hours to equilibrate to room 
temperature. Mice were placed in the sink individually and their ability to swim 
was assessed for one minute. Normal swimming behavior was noted when the 
animal kept its body aligned horizontally in the water with its nose clearly above 
the surface. Abnormal swimming was noted when the animal made vertical 
deviations, had substantial head tilt, assumed an immobile floating position, or 
had significant lower limb thrashing. Any abnormal swimming was scored as a 
failure. Mice were scored on a two-point system, either succeeding or failing the 
test.  
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RESULTS 
 
Postn-Cre+ mice develop schwannomas 
Initial studies demonstrated that all Postn-Cre; Nf2flox/flox mice sacrificed at 15 
months of age possessed significant enlargements of the dorsal root ganglion 
(DRG) and proximal spinal nerve roots (Figure 2A and 2B). Subsequent 
histologic analyses indicated these enlargements are present at every vertebral 
level in Postn-Cre; Nf2flox/flox mice. To better understand the time course of these 
enlargements, we sacrificed and dissected mice at multiple time points. By five 
months of age, all Postn-Cre; Nf2flox/flox mice acquired enlargements of their DRG 
and proximal spinal nerve roots, with microscopic evidence of Schwann cell 
hyperplasia and/or schwannoma, featuring dense, intersecting fascicles of 
Schwann cells (Figure 3). By eight months, all Postn-Cre; Nf2flox/flox mice 
demonstrated DRG and proximal spinal nerve tumors with histological 
characteristics of frank schwannoma (Figure 2C and 2D). Further analyses 
demonstrated diffuse S100-positivity of tumors from Postn-Cre; Nf2flox/flox mice, 
consistent with previously established criteria for genetically engineered mouse 
(GEM) Grade I schwannoma (Figure 2E) [34]. At fifteen months, dissected spinal 
cords from Postn-Cre; Nf2flox/flox mice demonstrated more than a five-fold 
increase in DRG volume as compared to Cre-negative control littermates (Figure 
2F). Thus, Postn-Cre; Nf2flox/flox mice develop slow growing, low-grade 
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schwannomas highly reminiscent of schwannomas observed in individuals with 
NF2.  
 
Detailed temporal analysis of cohorts revealed that Postn-Cre; Nf2flox/flox mice had 
a reduced lifespan as compared to Cre-negative Nf2flox/flox control mice (Figure 
2G). In the majority of mice, only multiple large schwannomas were observed. 
However, 5/16 Postn-Cre; Nf2flox/flox mice analyzed required sacrifice due to the 
development of tumors that, upon histological examination, were found to be 
GEM Grade III lesions consistent with malignant peripheral nerve sheath tumors 
(MPNST) (Figure 4). MPNSTs, malignant sarcomas, and malignant carcinomas 
have also been observed with disruption of Nf2 in other genetically engineered 
models [75].  
 
Detailed examination of schwannomas excised from Postn-Cre; Nf2flox/flox mice 
indicated these tumors possessed an architecture highly reminiscent of 
schwannomas found in human NF2 disease. Some nerves demonstrated 
discrete nodules of schwannoma, similar to the Schwann cell tumorlets 
commonly observed in the cauda equina of NF2 patients (Figure 5A) [77]. In 
multiple cases, proliferating schwann cells caused diffuse expansion of the nerve 
and extended into its ramifications, simulating plexiform schwannomas frequently 
encountered in human NF2 patients (Figure 5B). Other focal lesions 
demonstrated pseudo-onion bulb formations comprised of proliferating Schwann 
20 
 
cells tightly whorled around a central axon, a histological feature also found in 
some human NF2-associated schwannomas (Figure 5C). Finally, in some 
nerves, proliferating Schwann cells did not form a discrete mass, but rather 
exhibited diffuse regions of hypercellularity, possibly representing an early 
neoplastic change prior to schwannoma development (Figure 5D). 
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Figure 2. Postn-Cre; Nf2flox/flox 
 
mice develop schwannomas of the DRG and 
spinal nerves.  (A and B) Dissected spinal cord of 15 month old Cre-negative 
control (A) and Postn-Cre; Nf2flox/flox (B) mice, with Postn-Cre; Nf2flox/flox mice 
displaying diffusely enlarged DRG and spinal nerves (red arrowheads).  (C and 
D) Hematoxylin and Eosin (H&E) stain of the DRG from seven month Cre-
negative control and Postn-Cre; Nf2flox/flox mice, respectively. The whorls of 
Schwann cell proliferation observed in D are characteristic of schwannoma 
histology. Original magnification x200.  (E) Immunohistochemical S100 stain 
indicating tumors are comprised of mature Schwann cells. Original magnification 
x400.  (F) DRG volume quantitation of 15 month old Cre-negative control mice 
(4) and Postn-Cre; Nf2flox/flox mice (6). P < .0001, Unpaired Student’s T-test with 
Welch’s correction.  (G) Kaplan-Meier survival analysis of Cre-negative control 
mice (8) and Postn-Cre;Nf2flox/flox
 
 mice (16). P < .001, Log-Rank (Mantel-Cox) 
Test.  
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Figure 3. Temporal analysis of spinal nerve tumors in Postn-Cre; Nf2flox/flox 
mice.  (A and B) Gross dissected spinal cord and H&E stain from representative 
5 month old Cre-negative control (A1 and A2) and Postn-Cre;Nf2flox/flox mouse 
(B1 and B2), respectively.  Red arrowheads in B1 highlight the spinal 
enlargements observed in the Postn-Cre; Nf2flox/flox mouse at 5 months of age. 
A2 and B2, original magnification x400. 
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Figure 4. A small percentage of schwannomas in Postn-Cre; Nf2flox/flox mice 
progress into MPNSTs.  (A) H&E stain of a GEM Grade III tumor (MPNST) 
observed in a Postn-Cre; Nf2flox/flox mouse, showing that some schwannomas 
progress into malignant Schwann cell tumors with large, pleomorphic cells 
arranged in intersecting fascicles.  These tumors were diffusely infiltrative, 
possessed regions of necrosis, and also included mitotic figures.  This mouse 
was sacrificed at the age of seven months.  A1, original magnification x100.  A2, 
original magnification x200. 
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Figure 5. Schwannomas observed in Postn-Cre; Nf2flox/flox mice 
histologically resemble those observed in human patients.  (A) H&E stain 
showing a multifocal pattern of schwannoma growth along a nerve (red 
arrowheads). Original magnification x100.  (B) Example of a plexiform 
schwannoma involving a nerve twig with peripheral axons.  Original magnification 
x400.  (C) Pseudo-onion bulb formation of proliferating Schwann cells forming 
whorls around centrally-located axons within a nerve.  Original magnification 
x200.  (D) Diffuse spinal nerve hyperplasia observed in the nerve of a Postn-Cre; 
Nf2flox/flox mice.  Original magnification x400.  
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Vestibular schwannomas in Postn-Cre+ mice 
NF2 patients develop schwannomas in multiple anatomic regions, including 
peripheral, cranial, and spinal nerves [78]. Interestingly, by ten months of age, 
thorough dissection and histological analysis of each Postn-Cre; Nf2flox/flox mouse 
revealed schwannomas in nearly all histological specimens of peripheral, cranial, 
and spinal nerves. For example, all Postn-Cre; Nf2flox/flox mice examined for 
cranial nerve pathology featured schwannomas of the Trigeminal (CN V) and 
Facial (CN VII) nerves (Figure 6). Given the high correlation between human 
NF2 disease and the presence of bilateral vestibular schwannomas, we focused 
on CN VIII and its associated functions. Histological analysis of Postn-Cre; 
Nf2flox/flox mice revealed aberrant Schwann cell growth in CN VIII proximal to its 
entry into the inner ear, including tumors observed in Scarpa’s ganglion, the 
anatomic site of the afferent nerve cell bodies prior to their synapse with 
vestibular hair cells (Figure 7A and 7B). Postn-Cre; Nf2flox/flox  mice also 
demonstrated Schwann cell hyperplasia in the spiral ganglion (Figure 7C), a 
structure containing nerve cell bodies that transmit sound-derived nerve impulses 
from the cochlea to the brain. We observed none of these aberrations in Cre-
negative littermates. Importantly, the cochlea did not display any other obvious 
structural differences between the two genotypes (Figure 8).  
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Figure 6. Postn-Cre; Nf2flox/flox
 
mice develop schwannomas on CN V and CN 
VII.  (A and B) Representative H&E stains of CN V (A) and CN VII (B) from 
Postn-Cre; Nf2flox/flox  mice displaying schwannoma development in the cranial 
nerves.  Original magnification x200. 
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Figure 7. Postn-Cre; Nf2flox/flox
 
mice develop schwannomas on CN VIII.   
(A1) H&E stain of a vestibular schwannoma located in Scarpa’s ganglion (ScG). 
Original magnification x100.  In the 200x magnified inset image (A2), notice the 
Schwann cell proliferation displacing nerve cell bodies (black arrows) and 
pushing axons to the periphery of the nerve (red arrowheads).  (B) Diffuse 
hypercellularity observed in CN VIII. Original magnification x100.  (C1) Schwann 
cell proliferation in the spiral ganglion (SpG), expanding and disrupting the 
architecture of the ganglion. Original magnification x100.  In the magnified (400x) 
inset C2, notice the dysplastic, irregularly spaced Schwann cells.  Cochlea (Co), 
Scala Media (SM), Scala Vestibuli (SV), Scala Tympani (ST). 
  
28 
 
 
Figure 8. The cochleas in Postn-Cre; Nf2flox/flox mice are structurally similar 
to Cre-negative controls.  (A and B) Toludene Blue stain of the spiral ganglion 
and cochlea showing that cochleas of Postn-Cre;Nf2flox/flox mice (B) are 
structurally comparable to their Cre-negative (A) age-matched counterparts (16 
months), save for schwannoma/Schwann cell hyperplasia present in the spiral 
ganglion (red arrowheads).  Original magnification x100. 
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Postn-Cre+ mice experience hearing loss and vestibular impariment 
To correlate these CN VIII lesions with potential functional hearing deficits, we 
used click-evoked auditory brainstem response (ABR) testing, a standard method 
to assess hearing loss in humans and small animals [79]. ABRs are electrical 
potentials recorded from electrodes placed on the scalp and near the ear. In 
response to sound stimuli, a characteristic ABR waveform with a series of peaks 
and troughs is observed, where peaks correspond to different components of the 
ascending auditory pathway [80]. We tested cohorts of mice at three, six, eight, 
and ten months of age, finding a progressively increasing ABR threshold in 
Postn-Cre; Nf2flox/flox mice, while control mice maintained a relatively consistent 
hearing threshold throughout the study (Figure 9A and 9B). Given that this click-
ABR screening was limited to a stimulus range from 30 – 90 decibel sound 
pressure level (dB SPL), and that the majority of Cre-negative mice exhibited 
robust waveforms at 30 dB SPL, it is likely that the mean differences between the 
two groups are even larger than those depicted in Figure 9B. Thus, the present 
data indicate a hearing loss that is temporally correlated with tumorigenesis in 
this mouse model. Functionally, a sensorineural hearing loss of this type would 
negatively impact a patient’s quality of life by limiting communication and social 
interaction in everyday listening environments with background noise.  
 
To expand our analysis of the hearing impairment in Postn-Cre; Nf2flox/flox mice, 
we studied the individual peaks present in click-ABR waveforms (Figure 9C and 
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9E). The first ABR wave (W1) represents potentials generated from the cochlear 
nerve [81]. The summating potential (SP), which appears as a small shoulder 
preceding W1, is largely comprised of potentials originating from the inner hair 
cells of the cochlea, with some contributions from outer hair cells [82, 83]. No 
significant differences were observed between Postn-Cre; Nf2flox/flox mice and 
Cre-negative control SPs at both the six and eight month time points, but a 
significant reduction in SP amplitude was observed in the Postn-Cre; Nf2flox/flox 
mice at ten months (Figure 9D). W1 amplitude was significantly attenuated in the 
Postn-Cre; Nf2flox/flox mice compared with Cre-negative controls at all of the tested 
time points (Figure 9F). The reduction in W1 amplitude at the six and eight 
month time points, when contrasted with the non-significant differences in SP 
amplitude, specifically points to a functional disruption in the cochlear synapse 
and/or cochlear nerve in Postn-Cre; Nf2flox/flox mice. These data also indicate a 
more extensive disruption of auditory function at the ten month time point, with 
decreased SPs suggesting diminished hair-cell function in addition to deficits in 
the cochlear synapse and/or cochlear nerve. Altogether, these studies reveal that 
Postn-Cre; Nf2flox/flox mice acquire sensorineural hearing loss that, in 
consideration of the schwannoma histopathology described in Figure 3, likely 
originates in the cochlear nerve. 
 
Vestibular schwannomas can also severely impair a patient’s sense of normal 
balance and orientation, leading to vertigo, nausea, accidents related to falls, 
and, thus, substantially decreased quality of life. In our studies with Postn-Cre; 
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Nf2flox/flox mice, we observed that some mice acquired a phenotype suggestive of 
vestibular dysfunction, as they exhibited head tilting, head tossing, head bobbing, 
and locomotive circling behavior. This behavior is collectively referred to as 
shaker/waltzer behavior, and has been observed in mice possessing defects in 
their vestibular organs [84, 85]. To test for vestibular dysfunction, we conducted 
three different behavioral tests to examine the integrity of the vestibular system 
[86]. Each mouse underwent a trunk curl, contact righting, and swim test on three 
occasions over the course of three consecutive days, with the results scored by 
two independent observers experimentally blinded to the genotype of the mice. 
Postn-Cre; Nf2flox/flox mice demonstrated profound impairment in their ability to 
successfully complete each of the three tests when compared to their Cre-
negative littermates (Table 1).  
  
32 
 
 
Figure 9. Postn-Cre; Nf2flox/flox mice show deficits in both threshold and 
supra-threshold auditory brainstem responses (ABRs).  (A) Representative 
ABR waveforms from individual Cre-negative (left) and Postn-Cre; Nf2flox/flox mice 
(right) at 10 months of age.  (B) Time-course click-ABR study quantitating 
differences between Cre-negative and Postn-Cre; Nf2flox/flox mice. Significant 
threshold elevations were seen in Postn-Cre; Nf2flox/flox mice at 8 (P < .01) and 10 
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(P < .001) months of age (n = 15, 12, 15, and 19 mice for 3, 6, 8, and 10 months, 
respectively). Thresholds were averaged across animals (mean ± SEM).  (C and 
D) The summating potential (SP) (C), dominated by inner-hair-cell receptor 
potentials and evident in the ABR waveform immediately preceding peak 1, is 
comparable in amplitude across groups at 6 and 8 months of age, but is reduced 
in Postn-Cre; Nf2flox/flox mice at 10 months (P < .001) (D).  (E and F) ABR wave 1 
(W1) (E), representing the summed response of the cochlear nerve, is reduced in 
Postn-Cre; Nf2flox/flox  mice compared to Cre-negative controls at all ages (P < .05, 
P < .05, P < .001) (F), indicating deficits in pre- and/or post-synaptic cochlear 
nerve function.  All statistical tests: two-way ANOVA with Bonferonni post-hoc 
analysis.  Thickness of waveforms (C and E) represent mean ± SEM.  
Amplitudes (D and F) represent high-level responses (across 60-90 dB SPL) 
averaged across animals (mean ± SEM).  Horizontal dotted lines (D and F) at the 
base of the y-axis indicate the noise floor measurement. 
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Table 1: Postn-Cre; Nf2flox/flox mice develop vestibular impairment.  
Results of examination of the vestibular system in Postn-Cre; Nf2flox/flox mice and 
Cre-negative controls.  Tests were conducted on three consecutive days and 
scored by two independent scorers experimentally blinded to the animal’s 
genotype.  Mice were scored on a two-point scale, either succeeding or failing a 
particular test.  A detailed description of the three tests can be found in the 
methods section.  All mice were 13 months old at the time of testing.  Fischer’s 
Exact Test was used to test for statistically significant differences. 
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Embryonic analysis of PostnCre+ progenitor populations 
To gain a more detailed understanding of the temporal, anatomical, and cellular 
origins of Nf2-associated schwannomas, we further characterized gene 
expression driven by the 3.9kbPeriostin promoter element. First, recombination 
of Nf2 was confirmed in the cranial and spinal nerves (Figure 10). Next, we 
performed embryologic studies with an intercross between Postn-Cre and 
Rosa26 lox-stop-lox LacZ reporter mice. By E12.5, robust β-galactosidase 
expression was observed in the DRG, facial ganglia, and the developing cranial, 
spinal, and peripheral nerves (Figure 11A, 11B, and 11C). Approximately half of 
Schwann cells derived from the sciatic nerve of adult mice demonstrated positive 
X-gal staining with universal S100-positivity (Figure 11D and 11E). In the DRG, 
nerve roots, and peripheral nerves of E14 and E14.5 tissue, β-galactosidase 
expression coincided with Brain Lipid-Binding Protein (Blbp) expression, an 
established immunological marker of Schwann cell precursors and immature 
Schwann cells (Figure 11F and 11G) [60]. Schwann cell precursors and 
immature Schwann cells are multipotential embryonic Schwann cell lineages that 
descend from neural crest cells and represent the progenitor cell populations that 
give rise to mature Schwann cells. Importantly, the time points of the X-gal 
stained embryos in Supplemental Figure 6 represent the transition from Schwann 
cell precursors (E12-E13) to immature Schwann cells (E13-E15) [60]. These data 
indicate that Postn-Cre is expressed in early multipotent glial cell populations, 
likely representing the tumor cell of origin for this model.  
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Figure 10: Postn-Cre induces recombination in neural crest-derived 
tissues.  (A) PCR analysis demonstrating that Postn-Cre induces recombination 
in adult nerve tissues, but not the blood. Blood was taken from the tail vein of a 
Postn-Cre; Nf2flox/flox mouse prior to sacrifice.  After sacrifice, spinal and 
Trigeminal nerve tissue were dissected from the same mouse.  DNA was then 
isolated from these tissues and used for PCR analysis.  The presence of the 
Nf2delta2 allele indicates recombination of the Nf2flox2 allele.  This is representative 
data of PCR analysis in three different Postn-Cre; Nf2flox/flox mice.  The Nf2flox2 
allele is 440 base pairs (bp), Nf2delta2 allele is 338 bp, and Postn-Cre is 450 bp in 
length. Trigeminal Nerve (TG Nerve). 
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Figure 11. Postn-Cre is expressed in multipotent embryonic Schwann cell 
lineages.  (A and C) Beta-Galactosidase activity in Postn-Cre; Rosa26 lox-stop-
lox Lacz embryos at indicated embryonic time points (A, E12.5; C, E14.5).  (B) 
Beta-Galactosidase activity in the DRG of an E13.5 embryo.  (D) Beta-
Galactosidase activity in cultured Schwann cells from the adult sciatic nerve of a 
Postn-Cre; Rosa26 lox-stop-lox LacZ mouse. Original magnification x400.  (E) 
S100 stain of cultured Schwann cells from the adult sciatic nerve of a Postn-Cre; 
Nf2flox/flox mouse.  All cells were found to be S100 positive.  Original magnification 
x200.  (F and G) Immunostaining of BLBP in X-gal stained E14.5 (F) and E14 (G) 
embryo sections.  BLBP is a marker of Schwann cell precursors and immature 
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Schwann cells.  F, Original magnification x100.  G, Original magnification x200. 
Neural Tube (NT), Dorsal Root (Dr), Ventral Root (Vr), Peripheral Nerve (PN). 
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DISCUSSION 
 
In this study, we describe a novel NF2 mouse model recapitulating schwannoma 
phenotypes found in human patients. NF2-associated schwannomas are most 
frequently located on CN VIII and/or the spinal roots, and these tumors are seen 
in nearly all NF2 patients [1]. The NF2 mouse model presented in this study 
develops tumors on both structures with complete penetrance, and it also 
demonstrates functional impairments in hearing and balance that are commonly 
associated with human vestibular schwannomas.  
 
The characteristics of this model permit three broad areas of translational study. 
First, the genesis of genetically engineered models and the use of genetic 
intercrosses to provide in vivo proofs of concept have recently resulted in 
advances in the understanding of tumor suppressor genes and their roles in 
regulating specific signalling pathways, including other neurocutaneous disorders 
such as NF1 and tuberous sclerosis [87-92]. While the NF2 gene product was 
identified as mutated in familial NF2 disease over 25 years ago, it remains 
unclear which pathways are critical to tumor development downstream of NF2 
[93]. This genetic model may provide the means for elucidating which signalling 
pathways downstream of NF2 are essential to schwannoma development. 
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Second, the utility of accurate preclinical models that allow physiologic testing of 
clinical phenotypes is particularly important for orphan genetic diseases such as 
NF2, where patient numbers limit the ability to conduct multiple meaningful trials. 
In the entire United States, it is estimated that there are 12,000 individuals that 
have NF2. Though nearly all patients acquire vestibular schwannomas, at any 
given time only a small number of patients are available for clinical trials. Thus, 
preclinical models that can effectively screen for pharmaceutical agents that have 
meaningful therapeutic benefit for schwannomas are essential for the 
advancement of NF2 therapies. Functional ABR assessment of hearing during 
studies utilizing this model provides a unique, non-invasive, and physiologically 
relevant measure for determining therapeutic efficacy of compounds. 
 
Finally, a preclinical model can assist in understanding the basic biology of the 
hearing loss associated with vestibular schwannomas, which is incompletely 
understood. Tumor size resulting in local compression of CN VIII does not 
appear to account completely for the onset and progression of hearing loss in 
NF2 patients [33]. Interestingly, the recent short-term improvements in hearing 
with Bevacizumab treatment of vestibular schwannomas in NF2 patients are not 
consistently associated with a reduction in tumor size [94]. It has also been 
suggested that biochemical disturbance of the inner-ear fluids could be the 
underlying cause of hearing loss related to these tumors [95]. Otoacoustic-
emission studies in patients with vestibular schwannomas support the hypothesis 
that some degree of hearing loss is cochlear in origin [96, 97]. Altogether, the 
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degree to which hearing loss in these patients is retrocochlear (thus likely 
originating in the cochlear nerve) or cochlear in origin remains an open question. 
Our studies suggest functional impairment of cochlear-nerve activity in Postn-
Cre; Nf2flox/flox mice at both early (six and eight months) and later (ten months) 
stages of disease progression. In contrast, Postn-Cre; Nf2flox/flox mice have 
significantly reduced summating potentials only at ten months, suggesting that 
the structures required for mechanoelectric transduction of sound prior to the 
inner hair cell-cochlear nerve synapse are not significantly impaired earlier in the 
disease process. These findings, in association with the neoplastic Schwann-cell 
accumulation and extensive morphologic changes seen in the spiral ganglion, 
strongly suggest that a significant component of the hearing loss in this model 
originates in the cochlear nerve. Evidence for an additional, later-onset 
dysfunction of cochlear origin comes from the combination of increased 
thresholds at ten months with further decreased wave 1 amplitude and 
decreased summating potential. In summary, these data suggest an early 
retrocochlear form of hearing loss beginning in the cochlear nerve, and, at later 
time points, a more extensive form of hearing loss incorporating both the 
cochlear nerve and cochlea. Further studies utilizing the Postn-Cre-based NF2 
mouse model may allow additional insights into this clinical question regarding 
the mechanisms of hearing loss present in vestibular schwannoma patients.  
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INTRODUCTION TO CHAPTER TWO 
 
NF-κB signaling pathway 
The NF-κB (nuclear factor kappa-light-chain enhancer of activated B cells) family 
of DNA-binding protein complexes was first identified as a B-cell specific 
transcription factor in 1986 [98].  Subsequent work by the same group discovered 
that this family of proteins possessed inducible DNA-binding activity and was 
expressed in a wide-variety of cell types [99, 100].  In the nearly 30 years since, 
NF-κB has emerged as a major regulator of immunity and inflammation, among a 
host of other basic functions in cellular physiology [101, 102]. 
 
The NF-κB family of transcription factors is comprised of NF-κB1/p105, NF-
κB2/p100, RELA, RELB, and c-REL.  All of these transcription factors possess an 
N-terminal Rel homology domain (RHD), which is known to mediate both the 
homo-/heterodimerization characteristic of NF-κB proteins as well as their DNA-
binding sequence specificity.  NFκB1 and NFκB2 encode the precursor proteins 
p105 and p100, respectively, which are subsequently processed to their 
transcription factor counterparts, p50 and p52.  RELA, RELB, and c-REL contain 
a C-terminal transcriptional activation domain (TAD) which distinguishes them 
from p50 and p52.  Thus, p50 and p52 rely on dimerization with other Rel family 
members to promote the transcription of target genes[103].  RELA and c-REL 
preferentially interact with p50 [104], while RELB is predominantly found with 
p100 or p52 [105-107]. 
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Dimers of NF-κB transcription factors are largely regulated by nucleo-cytoplasmic 
shuttling.  The principal mediators of this regulation are the IκB proteins, also 
known as the inhibitors of NF-κB [104]. IκB proteins possess multiple ankyrin 
repeats that are responsible for the binding of NF-κB transcription factors.  Their 
ability to sequester NF-κB proteins in the cytoplasm depends on their ability to 
obscure the nuclear localization signal present in the NF-κB proteins.  Though 
there are a number of IκB proteins, this introduction will only focus on IκBα, a 
classical IκB, and p100, an atypical IκB. RELA:p50 heterodimers are primarily 
held in the cytoplasm by IκBα [104].  p100 is thought to predominantly bind RELB 
in the cytoplasm, while not having a substantial effect on other NF-κB proteins 
[105-107].  Some have reported that p100 may also play a role in regulating 
RELA localization, however [108].  p105 contains C-terminal ankyrin repeats and 
does possess IκB activity for p50, RELA, and c-REL, but it is constitutively 
processed to p50 in unstimulated cells and primary function is believed to reside 
in the production of p50 [109-111]. In response to a broad set of stimuli that 
result in upstream NF-κB pathway activation, IκB proteins are degraded by the 
proteasome [101].  For example, IκBα is rapidly degraded in response to TNF-α 
and LPS, two well-studied activators of NF-κB.  NF-κB pathway activation also 
promotes the transcription of the gene encoding IκBα, which is one of the many 
examples of feedback regulation present in this particular pathway [112, 113]. 
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The most well-studied arm of NF-κB signaling, the canonical pathway, primarily 
results in the nuclear accumulation of p50:RELA and p50:c-REL heterodimers.  
The degradation of IκBα and nuclear translocation of NF-κB proteins depends on 
activation of the upstream IKK complex.  The IKK complex consists of the 
catalytically active IKKα and IKKβ subunits and the regulatory subunit NEMO 
(also referred to as IKKγ).  The activation of the IKK complex is intricate and 
quite different depending on the particular ligand/cognate receptor interaction, 
and as such is beyond the scope of this introduction.  Once activated, the IKK 
complex phosphorylates IκBα at Serine 32 and 36, promoting its K48-
polyubiquitination and degradation by the proteasome [104].  IKKβ is believed to 
be the major IκB kinase in most cell types [114]. 
 
The alternative or non-canonical NF-κB signaling pathway is not as well-studied 
as the canonical pathway.  In response to non-canonical NF-κB stimuli, NF-κB 
inducing kinase (NIK) is stabilized, resulting the phosphorylation and activation of 
its preferred substrate, IKKα [106, 115].  Activated IKKα homodimers 
phosphorylate p100 in its C-terminal ankyrin repeat domain, resulting in its 
polyubiquitination and partial processing by the proteasome.  This partial 
processing of p100 to p52 results in the accumulation of p52:RELB heterodimers 
that are free to translocate to the nucleus and induce target gene expression.  A 
diagram depicting the major proteins in both the canonical and non-canonical 
NF-κB signaling pathways is seen in Figure 12. 
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Figure 12. Schematic representation of the NF-κB signaling pathway. 
Diagram depicting a selected group of the critical proteins involved with canonical 
and non-canonical NF-κB signaling.  In the canonical pathway, upstream signals 
including cytokines and TNF ligands result in activation of an IKK complex 
comprised of IKKα and IKKβ.  IκB phosphorylation by IKKβ leads to proteosomal 
degradation of IκB, freeing p50:RELA dimers to translocate to the nucleus and 
transactivate target genes.  In the non-canonical pathway, ligands such as 
BAFF/LTβ induce NIK stabilization. NIK stabilization is sufficient to activate an 
IKKα homodimeric complex, which phosphorylates p100, leading to its 
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proteosomal processing to p52.  The degradation of p100 allows p52:RELB 
complexes formerly sequestered in the cytoplasm to translocate to the nucleus 
and induce the expression of target genes. NF-κB target genes include those 
known to promote survival, proliferation, and inflammation.  Notice that NIK is 
placed upstream of both pathways, as it is sufficient to activate both canonical 
and non-canonical NF-κB signaling. 
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Interestingly, canonical NF-κB pathway activation can also feed into the non-
canonical pathway. NFκB2, the gene encoding p100 is a known target gene of 
the canonical pathway [116].  This suggests the possibility of synergistic 
crosstalk between the canonical and non-canonical NF-κB pathways.  An 
observation supporting this theory is that basal RELA NF-kB activity is required 
for LTβ-induced RELB:p52 dimer generation [117].  Given that four of the five 
RHD containing NF-κB transcription factors are encoded by canonical NF-κB 
target genes [116, 118-121], the pathway as a whole has been suggested to be 
dynamic in its ability to amplify and/or alter target gene expression [122].   
 
NIK, NF-κB, and cancer 
Previous studies of mice carrying a point mutation or knockout of NIK indicated 
its requirement in regulating the non-canonical NF-κB pathway [123, 124].  
Further study of NIK revealed it to be a tremendously unstable protein that is 
rapidly degraded in cells under basal conditions [125].  In response to certain 
ligands including CD40L, LTβ, and RANKL, NIK is stabilized, phosphorylating 
IKKα and inducing downstream p100 processing [125, 126].  NIK degradation is 
regulated by an E3 ligase complex comprised of TRAF2, TRAF3, c-IAP1, and c-
IAP2 [127, 128].  TRAF3 functions as a molecular tether to a complex of TRAF2 
and c-IAP1/2, in which c-IAP1/2 actually mediate the K48-polyubiquitination of 
NIK, targeting it to the proteasome for degradation (Figure 13).  
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Figure 13. Schematic representation of NIK degradation by an E3 Ligase 
protein complex including TRAF2, TRAF3, and c-IAP1/2.  NIK is a protein 
maintained at low basal levels due to constitutive turnover by the proteasome.  
TRAF3 interacts with NIK in its TRAF3 binding domain in the N-terminus, 
tethering it to an E3 complex containing TRAF2 and c-IAP1/2.  Once formed, c-
IAP1/2 mediates the K48-polyubiquitination of NIK, leading to its proteasomal 
degradation. 
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Recent Multiple Myeloma (MM) studies have provided additional insights into the 
mechanism of NIK degradation.  Many MM cell lines possess mutations/deletions 
in TRAF3 or NIK that preclude their interaction at the protein level, resulting in 
stabilization of NIK [129, 130].  Additional MM cell lines were found to have large 
deletions of the locus including BIRC2 and BIRC3, the genes encoding c-IAP1 
and c-IAP2, respectively [130].  A subset of MALT Lymphomas harboring an 
oncogenic fusion resulting in a c-IAP2-MALT1 fusion protein are also driven by 
stabilization of NIK signaling [131].  The resultant fusion protein is a protease 
with unique specificity for NIK, cleaving the N-terminus and removing the TRAF3 
binding domain.  The remaining NIK C-terminal fragment is resistant to 
proteasomal degradation and is now free to drive downstream oncogenic 
signaling.  Importantly, NIK stabilization is also capable of inducing canonical NF-
κB signaling through activation of IKKα\β heterodimers [129, 132].  It has 
previously been suggested that NIK’s ability to activate both pathways is a 
possible explanation for the multitude of genetic alterations observed in MM that 
all result in stabilization of NIK [133].  A trenchant explanation for the tight 
regulation of NIK at the protein level is that studies have shown NIK to be a 
constitutively activated kinase independent of additional post-translational 
modifications [134]. Overall, these studies implicate NIK as a potent oncogene 
and regulator of NF-κB signaling. 
 
The first direct connection between NF-κB activation and cancer came from the 
characterization of the viral homolog to c-REL, v-REL.  v-REL was shown to be a 
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driver of avian leukemias and lymphomas [135].  Further support of NF-κB’s role 
in oncogenesis is demonstrated by the observation of constitutive NF-κB activity 
in cancer cells derived from patients with MM, Acute Lymphocytic Luekemia 
(ALL), and Chronic Myelogenous Leukemia (CML) [136].  NF-κB is a well-
established regulator of normal lymphocyte development and physiology, and as 
such is capable of activating genes involved with cellular proliferation and 
survival [137]. Deregulation of NF-kB, which is seen in most cancers [138], can 
result in the expression of proteins regulating cell cycle progression and survival, 
including Cyclin D1, Cyclin D2, CDK6, c-Myc, c-Myb, BCL2, ERBB2, and MET 
[139-145].  Given the central role of NF-κB in integrating signals from a diverse 
array of stimuli and transducing these signals into vital basic cellular functions, 
one can begin to understand why many cancers co-opt this pathway for selective 
advantage. 
 
NF-κB and NF2 in the nervous system 
Since its initial discovery as an important regulator of hematopoietic cell function, 
the bulk of studies investigating pathologic roles for NF-κB focus on 
hematopoietic cell types.  Because of this bias, there exists a relative dearth of 
knowledge on the role NF-κB plays in non-hematopoetic cell types and solid 
tumor biology. Due to the focus of this manuscript on schwannomas, a peripheral 
nerve tumor, we now review what is known of NF-κB in cell types and tumors of 
the nervous system, with a particular focus on glial cells. 
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NF-κB signaling in glial cells is believed to be heavily inducible but possess low 
basal activity [146, 147].  Because of this inducible nature of NF-κB in glial cells, 
it has been suggested that NF-κB activity may be linked to pathologic events 
[148].  Spinal cord injury studies in a transgenic mouse conditionally 
overexpressing a non-phosphorylatable form of IκBα in astrocytes, a glial cell of 
the CNS, support this hypothesis [149].  The authors concluded that NF-κB does 
not play a substantial role in regulating normal astrocyte homeostatic function but 
it does clearly contribute to astrocyte chemokine secretion in response to spinal 
cord injury.  These studies demonstrated that by blocking NF-κB signaling in 
activated astrocytes, mice had fewer healing defects post-injury and glial scarring 
was reduced. 
 
Canonical NF-κB activity involving RELA is required for peripheral myelination of 
axons by Schwann cells, indicating this developmental program is regulated by 
NF-κB [68] .  In the sciatic nerves of rats, increased NF-κB activation was 
observed in pre-myelinating Schwann cells in vivo and in vitro.  Further evidence 
of this relationship was seen in Rela knockout mice, which failed to properly 
myelinate peripheral nerves.  Blocking NF-κB activity in Schwann cell and neuron 
co-cultures significantly attenuated myelination and, additionally, prevented the 
induction of OCT6, a transcription factor required for proper myelination. These 
data suggest that NF-κB signaling is an essential mediator of the pre-myelinating 
Schwann cell developmental stage.  Additional studies support the notion that 
NF-κB is a regulator of Schwann cell differentiation [150, 151].   
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Previous studies have indicated that, at the molecular level, schwannomas 
resemble Schwann cells at the pre-myelinating stage of differentiation.  In one 
immunohistochemical study, the investigators found that the schwannoma cells 
had lost expression of markers of a mature myelinated phenotype, including P0 
and MBP.  Rather, the schwannoma cells now expressed markers of embryonic 
Schwann cell lineages, including NGFR, NCAM, L1CAM, and OCT6 [152]. In a 
recent microarray study of schwannomas, the investigators also found that 
schwannomas possessed a molecular phenotype similar to that of pre-
myelinating Schwann cells [153]. This study made the observation that 
schwannomas overexpressed L1CAM, ITGA4, TFAP2A, CDH2, and CDH19, 
which are all molecular markers of developing Schwann cell lineages prior to a 
mature myelinated phenotype [60].   
 
Given that loss of NF2 is the rate-limiting step in schwannoma formation [74, 75, 
154], the above studies suggest a fascinating potential link between 
schwannomas, NF2, and NF-κB signaling.  Indeed, NF2 has been previously 
identified as a negative regulator of canonical NF-κB activation [155].  In a more 
recent study using human schwannoma cells, Cyclin-D1 and Survivin were found 
to be expressed in an NF-κB dependent manner in vitro [156].  Further, the 
authors observed that total RELA and Phosphorylated S536-RELA, a marker of 
canonical NF-κB activation and RELA nuclear localization, are increased in 
schwannoma cells when compared to normal nerves. 
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Another interesting potential link between NF2 and NF-κB comes from a study 
examining a different tumor in the nervous system called ependymoma.  
Ependymomas are observed in up to 50% of NF2 patients, and are the 3rd most 
common tumor observed in these patients behind schwannoma and meningioma 
[1].  In this study, the authors identified a recurring C11orf95-RELA oncogenic 
translocation in sporadic supratentorial ependymomas [157].  The resulting RELA 
fusion protein, which also contains the C11orf95 zinc-finger domain, 
spontaneously translocates to the nucleus to transactivate target genes.  
Transplantation of neural stem cells expressing this fusion protein into mice 
resulted in ependymoma formation and dramatically reduced survival when 
compared to mice transplanted with stem cells expressing WT RELA or a control 
vector.  These studies demonstrate that constitutive NF-κB signaling is sufficient 
to drive ependymoma development, a tumor NF2 patients are genetically 
predisposed to acquire.   
 
In summary, there exist several studies connecting NF2, NF-κB, and 
schwannoma formation.  The studies herein employ broad genomic analyses to 
further implicate NF-κB activation in schwannomas, and then examine NF-κB 
signaling in murine and human schwannoma.  Finally, we show activation of this 
pathway through an upstream regulator, NIK, is sufficient to increase the 
proliferation, survival, and adhesion of primary Schwann cells and, additionally, 
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induce a transcriptional profile that is remarkably similar to that observed in 
murine and human schwannomas.  
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MATERIALS AND METHODS 
 
Microarray and Ingenuity Pathway Analysis 
Previously published schwannoma microarray data [153] 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE39645) were 
downloaded from the Gene Expression Omnibus (GEO) and loaded into Partek 
Genomics Suite (Partek, Inc.).  In our analysis, we included 31 schwannoma 
samples and 8 control samples (the human Schwann cell group was excluded 
from the controls). The data were then quantile-normalized and differentially-
expressed genes (DEGs) were identified by ANOVA as those having P-values 
less than .05.  The Bejamini and Hochberg method was used to correct for 
multiple testing.  Further filtering of DEGs was completed to remove genes with 
fold changes between -2 and 2.  Network analysis was then completed with this 
DEG set with Ingenuity Pathway Analysis (IPA, QIAGEN Redwood City, 
www.qiagen.com/ingenuity). Microarray analysis and IPA were completed by the 
Indiana University School of Medicine Center for Computational Biology and 
Bioinformatics. 
 
Statistical methods 
Statistical analyses were performed with GraphPad Prism 6.0. As noted in the 
text, ANOVA or Student’s T-test was used to test for differences between 
samples.  Specific tests and significance levels can be found in the figures and 
figure legends. 
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Preparation of mouse Trigeminal nerves for RNA and protein studies 
Mice were sacrificed and Trigeminal nerve tissue was freshly dissected, minced 
with a scalpel, and washed 3 times with cold PBS, pelleting the tissue in between 
washes using a tabletop centrifuge (Eppendorf) at 4C.  Tissue was then prepared 
for protein or RNA studies.  For whole lysate protein studies, xTractor Lysis 
buffer (Clontech) with cOmplete Protease inhibitor cocktail (Roche) and 
PhosSTOP Phosphatase inhibitor cocktail (Roche) was incubated with the 
tissues.  This mixture was then sonicated on ice, spun down at max speed on a 
tabletop centrifuge for 10 minutes at 4C, and the supernatant was collected and 
stored at -80 for future use.  Trigeminal nerve tissue was fractionated into 
cytoplasmic and nuclear protein fractions using the NE-PER Subcellular 
fractionation kit (Thermo Pierce). For subsequent RNA extraction, tissues were 
suspended in RNALater (Life Technologies) and stored at -20.  
 
RNA extraction from Trigeminal Nerves and primary Schwann cells 
RNA extraction, cDNA synthesis, qRT-PCR, data acquisition, analysis, and QC 
of mouse Trigeminal nerve samples were completed by Genome Explorations 
USA (Memphis, TN).  All other RNA work was completed at Indiana University 
School of Medicine.  RNA was extracted from primary Schwann cells with Trizol 
(Life technologies).  QuantiTect Reverse Transcription kit (Qiagen) and Fast 
SYBR Green Real-Time PCR Master Mix (Life Technologies) were then used for 
two-step qRT-PCR with an ABI 7500 Fast Thermal Cycler.   
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qRT-PCR Primer list (all are targeted to genes in mice) 
gene/primer name Sequence 
Bcl2 For aagctgtcacagaggggcta 
Bcl2 Rev ctctcaggctggaaggagaa 
Birc2 For tgtggcctgatgttggataac 
Birc2 Rev ggtgacgaatgtgcaaatctact 
Birc3 For acgcagcaatcgtgcattttg 
Birc3 Rev cctataacgaggtcactgacgg 
Casp8 For tgcttggactacatcccacac 
Casp8 Rev tgcagtctaggaagttgacca 
Ccnd1 For tctttccagagtcatcaagtgtg 
Ccnd1 Rev gactccagaagggcttcaat 
Ccnd2 For gctgtgcatttacaccgaca 
Ccnd2 Rev acactaccagttcccactcca 
Erbb2 For gagacagagctaaggaagctga 
Erbb2 Rev acggggattttcacgttctcc 
Gapdh For aggtcggtgtgaacggatttg 
Gapdh Rev  tgtagaccatgtagttgaggtca 
Met For gtgaacatgaagtatcagctccc 
Met Rev tgtagtttgtggctccgagat 
Nfkb1 For tcaggtgcagtgtcttgagc 
Nfkb1 Rev ggagggacagcagtaacaaca 
Nfkb2 For agtgtgcgctgtgtctgtag 
Nfkb2 Rev gttcttcttggttacatgcagga 
Rela For tgcccagaccgcagtatc 
Rela Rev ggattcgctggctaatgg 
Relb For gtgacctctcttccctgtcact 
Relb Rev tgtattcgtcgatgatttccaa 
Rel For agaggggaatgcggtttagat 
Rel Rev ttctggtccaaattctgcttcat 
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Procurement and preparation of human vestibular schwannoma tissue for 
protein and histological studies 
Freshly excised tumor specimen was snap frozen and stored in liquid nitrogen.  
Tissue was then prepared for protein studies similar to the procedure outlined 
above for murine nerve tissue.  Preparation of tissues for histological studies was 
completed as per the fixation and embedding protocol outlined in Chapter One 
for murine nerve tissues.  All studies were conducted under IRB approval 
(IRB#  1107006213, “Genotype, Phenotype, and Treatment of Human Vestibular 
Schwannomas.”). 
 
Primary antibody list 
The following antibodies were used for Western Blotting experiments: RELA (Cell 
Signaling #8242), RELB (Cell Signaling #4954), p100/p52 (Cell Signaling #4882), 
c-REL (Cell Signaling #12707), GAPDH (Cell Signaling #5174), NIK (Cell 
Signaling #4994),  IKKα (Cell Signaling #2682),  IκBα (Cell Signaling #4814), 
Myc (Cell Signaling #2278), HA (Cell Signaling #3724), FLAG (Cell Signaling 
#8146), NF2 (Abcam ab30329), and Caspase 8 (Santa Cruz sc-6136).  The 
custom polyclonal NIK antibody targeting murine NIK residues 311:328 was 
generated by Thermo Pierce custom antibody services.  For IHC/IF, the following 
antibodies were used: RELA (Santa Cruz sc-109), RELB (Santa Cruz sc-226), 
NIK (Santa Cruz sc-7211), GFP (Abcam ab1218), and S100 (Dako IS504). 
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Western Blot densitometry 
Western blot film was scanned into a digital format and intensity values were 
determined using the Image Studio Lite Version 3.1 (LI-COR Biosciences). 
 
Histology and immunohistochemistry 
Immunohistochemistry for RELA (Santa Cruz, sc-109), RELB (Santa Cruz, sc-
226), and NIK (Santa Cruz, sc-7211) using formalin-fixed, paraffin-embedded 
mouse and human samples was completed by the Indiana University School of 
Medicine Immunohistochemistry core.  RELA and RELB were visualized using 
the Dako EnVision+ Rabbit system and NIK was visualized with the DAKO Flex 
HRP system.  Schwannoma tissue microarrays (US Biomax) stained for RELA 
and NIK were also completed by the Indiana University School of Medicine 
Immunohistochemistry core. 
 
Cell culture and transfection  
HEK-293T cells (American Type Culture Collection, ATCC) were used for 
transfection experiments with polyethyleneimine (PEI, Sigma).  Unless otherwise 
noted, Dulbecco’s Modified Eagle Medium (DMEM, Gibco/Invitrogen) containing 
10% Fetal Bovine Serum(Sigma), 50 U/mL penicillin, 50 ug/mL streptomycin, and 
2mM L-Glutamine(Lonza) was used for cell culture.  For creation of a stable NF-
κB reporter cell line, 293T cells were transduced with Cignal NF-κB GFP 
Reporter Lentivirus (Qiagen) and selected with puromycin (Sigma).  The Cignal 
NFκB GFP Lentivirus stably inserts a modified form of the GFP gene under the 
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control of a minimal CMV promoter with tandem repeats of the canonical NF-κB 
transcriptional response element. 
 
Plasmids and site-directed mutagenesis 
C-terminal Myc/FLAG-tagged full-length (FL) NIK and Caspase-8 cDNAs in the 
PCMV6-Entry vector were purchased from Origene.  The Caspase-8 cDNA was 
then shuttled into the PCMV6-AC-HA backbone (Origene) using the Sgf1 and 
Mlu1 restriction sites.  N-Myc FL NIK, N-Myc and C-FLAG 309-801 NIK were 
PCR-amplified (adding epitope tag sequences and cloning sites) using Phusion 
Hi-Fidelity polymerase (New England Biolabs) from a vector containing FL NIK, 
subcloned into a TOPO-TA cloning vector (Life Technologies), and then cloned 
into the PCMV6-XL5 backbone (Origene) using the EcoRI and SalI cloning sites.  
The pCR-FLAG-IKKalpha-KM, pFlag-CrmA, and pcDNA-CrmA plasmids were 
acquired from Addgene.  Site-directed mutagenesis of FL NIK was completed 
using the New England Biolabs Q5 QuickChange Site-Directed Mutagenesis kit 
and validated by Sanger sequencing.  The NEBaseChanger web application was 
used for primer design.   
 
Virus generation and titration 
The puc2CL6IEGwo Lentiviral IRES-EGFP construct was a kind gift of Helmut 
Hannenberg at Indiana University School of Medicine.  Using standard molecular 
cloning techniques, we cloned C-FLAG 309-801 NIK into the puc2CL6IEGwo 
construct using the EcoRI and BamHI cloning sites.  The puc2CL6IEGwo 
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construct contains an IRES-EGFP cassette and multiple cloning site downstream 
of the spleen focus-forming virus (SFFV) promoter, which robustly drives 
transcription in Eukaryotic cells.  To generate virus, 293T cells grown to 70% 
confluence were transfected with 10 ug each of C-FLAG 309-801 NIK 
puc2CL6IEGwo (Lenti 309-801 NIK) or empty vector puc2CL6IEGwo (Lenti IRES 
EGFP), 5 ug of gag-pol expressing plasmid, and 1 ug of foamyviral envelope 
containing plasmid (PCOPE01) in 6 mL of Dulbecco’s Modified Eagle Medium 
(DMEM, Gibco/Invitrogen) containing 10% FBS and 0.0075 mg/mL 
polyethyleneimine (PEI, Sigma).  After roughly 16 hours of transfection at 37C, 
transfection media was replaced with 6 mL fresh DMEM containing 10% FBS, 50 
U/mL penicillin, 50 ug/mL streptomycin, 2mM L-Glutamine(Lonza).  After 24 
hours, cultures were collected and filtered through a .22 um polyethersulfone 
(PES) membrane Stericup unit (Millipore) and centrifuged at 30,000 x g at 4C for 
2 hours in a polycarbonate Oak Ridge centrifuge tube (Nalgene).  Supernatant 
was then decanted, bleached, and placed in biohazard waste. The viral pellet 
was then resuspended in 1 mL of DMEM containing 10% FBS.  Virus was then 
stored in aliquots at -80C.  Titration of virus to calculate effective infectious 
particles per unit volume (Transduction Units, or TU, per mL) was determined by 
percent GFP-positivity (as measured by flow cytometry) of serially transduced 
HT1080 cells plated at 100,000 per well on a six-well plate in 1 mL of 
DMEM/10% FBS.  Serial dilutions started at 10-3 and ended with 10-8 dilution.   
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Primary Schwann cell procurement and culture 
Wild type (WT) embryonic day 13.5 (E13.5) embryos were harvested from 
pregnant dams after sacrifice. The dorsal root ganglion (DRG) was then 
dissected from each embryo with the aid of a dissecting microscope.  The DRGs 
were then digested in Trypsin and dissociated with syringes.  Individual DRGs (a 
collection from a single embryo) were then plated on Poly-D-Lysine (PDL, 
.1mg/mL)/Laminin (.25mg/mL, Sigma) coated 12-well plates at one embryo per 
well in Schwann Cell Media I (SCM-I) comprised of DMEM with 50 U/mL 
penicillin, 50 ug/mL streptomycin, 2mM L-Glutamine(Lonza), 1X N2 supplement 
(Life Technologies), and 250 ng/mL Nerve Growth Factor (NGF, Sigma).  The 
following day, the media was changed to Schwann Cell Media II (SCM-II), which 
was identical to SCM-I except for the substitution of 2 uM Forskolin and 10 ng/mL 
Neuregulin (Sigma) for NGF. 
 
Transduction of primary Schwann cells 
Three days after harvesting and plating WT Schwann cells on 12-well plates, 
cells were then transduced with Lentivirus in 1 mL of SCM-II at a MOI of 20 
(based on an approximate cell number of 200,000 cells per well).  Cells were 
incubated in SCM-II with virus for 72 hours before replating.  All experiments 
utilized passage 1 Schwann cells. 
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Schwann cell proliferation assays 
Hemacytometer-based: 200,000 Schwann cells of each genotype were seeded in 
triplicate on a PDL/Laminin-coated 12-well plate and allowed to adhere overnight.  
The following morning, the media was changed to fresh SCM-II, and 72 hours 
later the cell number in each well was calculated by Trypan Blue exclusion with a 
hemacytometer. 
 
EdU with fluorescent microscopy: 200,000 Schwann cells of each genotype were 
plated on coated coverslips in 12-well plates.  The following morning, the media 
was changed to fresh SCM-II with 10 uM EdU.  Cells were pulsed for 8 hours and 
fixed.  Life Technologies  Alexa 594 EdU Imaging kit was used to complete the 
staining of the cells.  Coverslips were then imaged on the deconvolution 
microscope. 
 
Schwann cell survival assay 
In a PDL/Laminin-coated 12-well plate, 200,000 Schwann cells of each genotype 
were seeded in triplicate and allowed to adhere overnight.  The following day, the 
media was removed, cells washed 1X with PBS, and growth-factor free DMEM 
with 50 U/mL penicillin, 50 ug/mL streptomycin, and 2mM L-Glutamine was 
added.  The number of living cells in each well was counted 48 hours later by 
Trypan Blue exclusion with a hemacytometer. 
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Schwann cell adhesion assay 
For measurement of cell adhesion, the ACEA iCelligence system was used.  The 
iCelligence system uses an impedance calculation that allows for real-time 
monitoring of diverse cellular processes, including cellular adhesion.  First, E-
plates (ACEA) were coated with PDL/Laminin and 250 uL of SCM-II was added 
to the plates to take an initial impedance reading.  Next, IRES-EGFP and 309-
801 NIK Schwann cells were added to the wells at 25,000 cells/well with a final 
volume of 500 uL.  Impedance values were measured every second for the 
following three hours. 
 
Cycloheximide NIK protein stability assay 
293T cells at 70% confluency in 10 cm dishes (BD Falcon) were transfected with 
4 ug/dish of FL N-Myc NIK or N-Myc 309-801 NIK for 36 hours prior to addition of 
media containing 10 ug/mL Cycloheximide (Sigma).  Cells were then lysed at the 
indicated conditions/time points and the protein visualized by SDS-PAGE. 
 
Immunoprecipitation experiments in 293T cells 
Immunoprecipitation experiments were completed in 293T cells transfected with 
the indicated plasmids/concentrations at 70% confluency in 10 cm dishes.  Two 
days after transfection, cells were lysed with RIPA Buffer (50 mM Tris-HCl pH 
8.0, 150 mM NaCl, 1% Triton X-100, .5% Sodium Deoxycholate, .1% SDS, 
protease and phosphatase inhibitors), sonicated, and samples were standardized 
by BCA (Thermo Pierce).  Samples were then incubated overnight with M2 Flag 
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Affinity Gel (Sigma).  Immunoprecipitated proteins were then visualized with 
SDS-PAGE.   
 
In vitro Caspase-8 cleavage assay 
Purification of FLAG-NIK: FLAG-NIK was transfected at 20 ug/dish in 70% 
confluent 15 cm dishes and harvested 48 hours later in Lysis Buffer (25 mM 
HEPES pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, protease and 
phosphatase inhibitors) and sonicated.  These samples were then incubated 
overnight with M2 Flag Affinity Gel.  Flag NIK was then eluted from the resin with 
100 uL of Flag peptide elution solution (200 ug/mL in TBS, Sigma).   
 
In vitro Caspase-8 cleavage of NIK: 200 ng of activated Caspase-8(BD) was 
added to 200 ng of purified NIK protein in a 50 uL volume of reaction buffer (20 
mM HEPES pH 7.4, 20 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1.5 mM MgCL2, 10 
mM DTT) for 1 hour at 37C.  Q-VD-Oph, an irreversible pan-caspase inhibitor, 
was purchased from ApexBio.   
 
Prediction of Caspase-8 cleavage sites and orthologous cleavage site 
analysis 
Caspase-8 cleavage sites were predicted for human NIK using two different 
applications, Cascleave 2.0 [158, 159] and SitePrediction [160].  Cascleave 2.0 
was set to a medium stringency threshold for prediction of cleavage sites.  The 
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NCBI homologene application was used to identify orthologous cleavage sites in 
chimpanzee, macaque, mouse, rat, dog, and cow.   
 
Deconvolution microscopy 
Cells were fixed in 4% Paraformaldehyde on coverslips in 12-well plates (BD 
Falcon). Following fixation, coverslips were washed 2X in PBS and 
permeabilized in .2% Triton X-100 in PBS and Blocked in .2% Triton X-100, 2% 
BSA in PBS.  Coverslips were then incubated with primary antibody in 1% BSA in 
PBS overnight at 4C, washed three times in PBS, and subsequently incubated 
for one hour at room temperature with fluorophore-conjugated anti-mouse or anti-
rabbit antibodies (Molecular Probes, Invitrogen).  After washing in PBS three 
times, coverslips were then incubated in PBS containing Hoescht and Phalloidin 
(Life Technologies) to stain the nuclei and actin cytoskeleton, respectively. 
Coverslips were then sealed on microscope slides (Fischer Scientific) with 
lacquer and allowed to dry overnight.  Data were acquired on a DeltaVision 
deconvoloving microscopy system (Applied Precision).  Typical controls included 
cells incubated with secondary (fluorophore-conjugated) antibody but not primary 
antibody. 
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RESULTS 
 
Genomic studies indicate NF-κB is activated in schwannomas 
In an effort to better understand the signaling pathways deregulated in human 
schwannomas, we retrieved and re-analyzed published microarray data [153] 
from a recent study on the Gene Expression Omnibus [161, 162].  In this study, 
31 human vestibular schwannomas were compared to normal nerve samples.  
After generating a set of differentially expressed genes (DEGs), we input this 
gene set into Ingenuity Pathway Analysis (IPA) to identify activated 
transcriptional modules and signaling pathways.  IPA canonical pathway and 
upstream regulator analyses both identified the NF-κB pathway as deregulated in 
schwannomas (Figure 14A).  A number of genes formerly identified as either 
regulated by NF2 or overexpressed in schwannomas are NF-κB target genes, 
including CCND1, ERBB2, and MET, and were also overexpressed in this 
dataset (Figure 14B) [139, 143, 145, 163-167].  To validate these deregulated 
genes, we performed qRT-PCR on primary nerve tissue from WT (Postn-Cre-
;Nf2flox/flox) and NF2-KO mice (Postn-Cre+;Nf2flox/flox, Figure 14C).  All genes 
listed in Figure 14B with the exception of Bcl2 (P = .073) were also 
overexpressed in murine schwannomas.   
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Figure 14. Ingenuity Pathway Analysis and qRT-PCR in schwannomas 
suggests activation of the NF-κB pathway. (A) Ingenuity Pathway Analysis 
(IPA) of human schwannoma microarray data.  IPA Canonical Pathway analysis 
indicated significant deregulation of NF-κB signaling, with 32 genes in the human 
schwannoma differentially expressed gene (DEG) group annotated as NF-κB 
signaling pathway members.  Similarly, IPA Upstream analysis indicated 61 
DEGs as NF-κB target genes. (B) Selected NF-κB target genes deregulated in 
human schwannomas, some of which have been previously identified as genes 
regulated by NF2. (C) Validation of the deregulated genes in B by qRT-PCR in 
primary nerve tissues derived from eight month old WT and NF2-KO mice. The 
experiment testing Birc2 and Birc3 included three WT and four NF2-KO mice.  All 
other genes tested included four WT and four NF2-KO mice.  ns = not significant, 
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* = P < .05, ** = P < .01, *** = P < .001; unpaired Student’s T test. Error bars 
represent SEM.  
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Increased expression of REL proteins in schwannomas 
Equipped with the knowledge that schwannomas from the NF2 mouse model 
resemble human schwannomas at the molecular level, we decided to examine 
these tumors for NF-κB activation.  qRT-PCR from age-matched primary nerve 
tissues revealed that all Rel family transcription factors were overexpressed at 
the RNA level (Figure 15A).  To see if this was also the case at the protein level, 
we analyzed whole lysate nerve tissues by SDS-PAGE.  Western blotting 
revealed increases in p100, RELA, RELB, and c-REL in NF2-KO tissues when 
compared to WT (Figure 15B).  p100, RELA, RELB, and c-REL are encoded by 
Nfkb2, Rela, Relb, and Rel genes, respectively.  We also observed an increase 
in p52 levels in NF2-KO nerve tissue.  The accumulation of p52 is an indicator of 
non-canonical NF-κB activation in murine schwannomas.  IκBα was increased in 
NF2-KO tissue at the protein level, and it appeared to migrate as a doublet in 
both WT and NF2-KO tissues (Figure 15B).  The upper band of IκBα was 
especially robust in the NF2-KO tissues, suggesting that a large fraction of the 
increased pool of IκBα was possibly phosphorylated and inactivated.  Overall, the 
increase in p100 and IκBα, IκB proteins, makes the net effect of the increase in 
RELA, c-REL, RELB, and p52 unclear, as it is possible that the increase in REL 
proteins is countered by the increase in IκB activity.  To address this question, 
we used Immunohistochemisty (IHC) and subcellular fractionation to localize the 
increase in REL proteins to the cytoplasm and nucleus. By IHC, we noted a 
diffuse increase in both cytoplasmic and nuclear accumulation of RELA in both 
mouse and human schwannoma (Figure 16).  Additional examples of the 
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increase in nuclear RELA staining in human schwannomas can be seen in 
Figure 17.  A diffuse increase in cytoplasmic and nuclear RELB staining was 
also seen by IHC in human schwannomas (Figure 18).  Finally, by subcellular 
fractionation, we further identified the increase in RELA and RELB in murine 
schwannomas to be both in cytoplasm and nucleus (Figure 19).  Altogether, 
these data indicate activation of both canonical and non-canonical NF-κB in 
schwannomas. 
 
The simultaneous increase in REL proteins and IκB proteins in schwannomas 
seemed unusual, as activation of NF-κB is typically paired with a decrease in IκB 
proteins.  We reasoned that chronic activation of NF-κB could result in 
upregulation of both REL family members and IκB proteins since they are 
encoded by genes upregulated by NF-κB, with the exception of RELA.  Indeed, 
similar observations have been made in Cylindromatosis, a disease exhibiting 
chronic activation of NF-κB.  In B-cells expressing a mutant form of CYLD, a 
gene encoding a NF-κB negative regulator and deubiquitinase, an increase in 
both IκBα and p100 was observed [168].  Yet CYLD mutant B cells still exhibited 
an increase in NF-κB DNA binding by Electrophoretic Mobility Shift Assays 
(EMSA) and, additionally, an increase in both cytoplasmic and nuclear RELB.  
Interestingly, human patients with germline mutations in CYLD develop multiple 
benign tumors of skin appendages.   
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Figure 15. Murine schwannomas exhibit increased levels of Rel 
transcription factors at the RNA and protein level. (A) qRT-PCR of NF-κB 
transcription factors in primary nerve tissue from WT and NF2-KO mice showing 
an increase in all Rel family members at the RNA level.  All experiments involved 
four WT and four NF2-KO mice, except for Rel, which included three WT and 
four NF2-KO mice.  ns = not significant, * = P < .05, ** = P < .01; unpaired 
Student’s T test. Error bars represent SEM. (B) Whole Lysate SDS-PAGE 
Western blot demonstrating an increase in NF-κB transcription factor and 
signaling pathway members at the protein level in NF2-KO nerve tissue.  Note 
the red asterisk next to p100, the protein encoded by the Nfkb2 gene and the red 
arrowhead next to p52, the resulting protein from p100 processing by the 
proteasome.  p52 accumulation, as seen in this blot, indicates activation of the 
non-canonical arm of NF-κB.  Increased IκBα was observed in murine 
schwannomas, which is an NF-κB target gene and a negative regulator of the 
canonical pathway. IκBα also migrated as a doublet in WT and NF2-KO tissues, 
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with an especially robust upper band in NF2-KO tissues.  All tissues are derived 
from eight month old mice.   
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Figure 16. Increased cytoplasmic and nuclear RELA reactivity observed by 
immunohistochemistry in murine and human schwannomas. (A and B) IHC 
of RELA in age-matched 12 month old murine WT (A) and NF2-KO DRG (B).  
Similarly, C and D present RELA IHC of control human nerve (C) and human 
vestibular schwannoma tissue (D), respectively.  Original magnification x400.  
Arrows in B and D point to nuclei with positive staining for RELA.  The magnified 
(1000x) images in the bottom right corner of B and D are examples of positive 
nuclear staining. 
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Figure 17. Expanded immunohistochemical panel of RELA in human 
schwannomas. (A-D) IHC of RELA in four different human schwannomas. Note 
that these tumors are not vestibular schwannomas. Arrows point to nuclei with 
positive staining for RELA. Original magnification x400.   
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Figure 18. Increased cytoplasmic and nuclear RELB reactivity observed by 
immunohistochemistry in human schwannomas. (A,B, and C) IHC of RELB 
in control human nerve tissue (A) and human vestibular schwannomas (HVS,B 
and C). Note the intense nuclear signal of RELB in vestibular schwannomas, in 
particular the tumor shown in B. Original magnification x400. 
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Figure 19. Increased cytoplasmic and nuclear RELA and RELB seen by 
subcellular fractionation in murine schwannomas. Subcellular fractionation 
and subsequent SDS-PAGE Western Blot of primary Trigeminal nerve tissue 
from age-matched eight month old WT and NF2-KO mice demonstrating a 
relative increase in cytoplasmic and nuclear levels of RELA and RELB proteins. 
The black line separating cytoplasmic and nuclear fractions in the RELA blots 
indicate different exposures of the cytoplasmic and nuclear fractions.  cyto = 
cytoplasmic fraction, nuc = nuclear fraction. 
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Schwannomas exhibit an increase in NIK and fragments of the NIK kinase 
domain 
Considering that our data indicated both the canonical and non-canonical NF-κB 
pathways were activated, we decided to look for upstream NF-κB regulators that 
are known to activate both pathways.  MAP3K14/NIK, a protein kinase, was first 
identified as an activator of the canonical pathway but is now better known as an 
essential regulator of the non-canonical pathway [126, 132, 169]. NIK-deficient 
human patients have been described, and isolated cells from these patients were 
deficient in both canonical and non-canonical NF-κB activation [170].  Further 
implication of NIK comes from previous studies utilizing NIK mutant and knockout 
mice, which exhibit decreased basal levels of Rel family proteins, suggesting that 
NIK signaling influences the overall levels of NF-κB transcription factors present 
in cells [171, 172].  If NIK does indeed regulate the level of Rel family proteins 
present in cells, then an increase in NIK signaling could explain the overall 
increase seen schwannomas.  Whole lysate SDS-PAGE analysis of primary 
nerve tissues from WT and NF2-KO mice for NIK revealed accumulation of 
fragments of the kinase domain of NIK the NF2-KO nerves, in particular a band 
that migrated around 55 kilodaltons (Figure 20A).  We also observed the 
presence of this 55 kD fragment of the kinase domain (p55 NIK) in three of three 
analyzed human vestibular schwannomas (Figure 20B).  In addition to this 
fragment, we saw a remarkable increase in full length (FL) NIK in the human 
tumors, which typically migrates around 120 kD.  In an expanded panel of murine 
tissues analyzed by SDS-PAGE, we saw a roughly three fold increase in FL NIK 
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in NF2-KO nerves (Figure 21).  IHC localized the increase in NIK to the 
tumorigenic cells in both human and murine schwannoma (Figure 22 and 23).  
Since NIK is a constitutively activated kinase [134], the relative increase in NIK 
between WT and NF2-KO tissues as measured by our Western Blotting studies 
could possibly explain the downstream activation of NF-κB.  Additionally, since 
cleavage of NIK to generate a stable, proteasome resistant fragment of the 
kinase domain has already been observed as a driver of cancer [131], we were 
intrigued to study the 55 kD fragment accumulating in both human and mouse 
schwannoma samples. 
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Figure 20. Accumulation of NIK and fragments of the NIK kinase domain in 
murine and human schwannomas. (A) Whole lysate SDS-PAGE Western blot 
demonstrating the accumulation of multiple fragments of the kinase domain of 
NIK in NF2-KO nerve tissue, including a 55 kD fragment indicated by the red 
arrowhead.  FL NIK can be identified by the red asterisk.  All tissues are derived 
from eight month old mice. (B) Similar to A, Western blot showing accumulation 
of a 55 kD fragment of the NIK kinase domain in three human vestibular 
schwannomas (HVS).  Note the increase in FL NIK seen in human tumors, 
indicated by the red asterisk.  The far two left lanes are mouse WT and NF2-KO 
tissues, respectively.   
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Figure 21. Accumulation of FL NIK and p55 NIK in murine schwannomas. 
Whole lysate SDS-PAGE Western blot of mouse primary nerve tissue showing 
accumulation of both the 55 kD fragment of the NIK kinase domain (red 
arrowhead) as well as FL NIK (red asterisk).  All tissues shown are from eight 
month old mice, save for the far two right lanes, which are from 12 month old 
mice. (B) Densitometry of FL NIK (red asterisk) in A.  ns = not significant, * = P < 
.05, ** = P < .01, *** = P < .001; unpaired Student’s T test.  Error bars represent 
SEM. 
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Figure 22. Immunohistochemistry localizes NIK accumulation to 
tumorigenic cells in schwannomas.  (A and B) IHC of NIK in age-matched 12 
month old murine WT (A) and NF2-KO DRG (B). (C and D) NIK IHC of control 
human nerve (C) and human vestibular schwannoma tissue (D). Original 
magnification x400.   
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Figure 23. Expanded immunohistochemical panel of NIK-positive human 
schwannomas.  (A-D) IHC of NIK in four different human schwannomas. 
Original magnification x400.   
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Caspase-8 cleaves NIK to generate a fragment of the kinase domain 
To our knowledge, only two previous studies have identified fragments of NIK 
and the proteases responsible for the cleavage event.  In the study mentioned 
previously [131], the authors found that a fusion cIAP2-MALT1 protease cleaved 
NIK at Arg-325, removing NIK’s TRAF3 binding domain.  Importantly, this study 
showed that wild type (WT) MALT1 does not demonstrate any protease activity 
on NIK.  Another study found that the cysteine-protease Caspase-8 was capable 
of cleaving NIK, generating fragments of the N and C-terminus [173].  The 
authors inferred from the migration of the fragments the actual sites of cleavage, 
and went on to build constructs that they used in overexpression studies.  No 55 
kD fragment of the kinase domain was observed, and none of the predicted NIK 
fragments were capable of activating NF-κB.  In this study, however, antibodies 
were used against the N and C-terminus of NIK, but no antibodies directed to 
internal regions of NIK were used.  Our Western Blotting experiments in 
schwannomas employed an antibody targeting an internal region of NIK 
surrounding Gly-659 of the kinase domain.  Thus, it remains an open question 
whether Caspase-8 cleavage of NIK can generate an internal fragment of NIK.  
We found that co-transfection of NIK and Caspase-8 in 293T cells resulted in the 
cleavage of NIK, generating a 55 kD fragment of the kinase domain (Figure 24).  
CrmA, a caspase inhibitor with high affinity for Caspase-1 and Caspase-8, 
inhibited Caspase-8 activation as seen by the abolishment of p43 and p18 
Caspase-8 fragments.  Procaspase-8 monomers are activated by dimerization 
and subsequent interchain proteolysis [174, 175]. CrmA inhibition of caspase 
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activity also prevented cleavage of NIK.  To confirm this cleavage event was 
specific to Caspase-8, we performed an in vitro cleavage assay with purified NIK 
and activated Caspase-8 (Figure 25), demonstrating that Caspase-8 does 
indeed cleave NIK, producing a 55 kD fragment of the kinase domain.  We did 
not detect any differences in Caspase-8 at the RNA level in NF2-KO tissues, but 
we did observe a decrease in Procaspase-8, which could mean increased 
processing of Procaspase-8 into its activated form in schwannoma samples 
(Figure 26). 
 
Caspase cleavage-mediated regulation of kinase function is a known 
phenomenon, with the bulk of studies focusing on this event in a pro-apoptotic 
context [176].  Importantly, NIK is a member of the STE family of kinases, in 
which there are many examples of caspase cleavage removing a negative 
regulatory region of the kinase, rendering the kinase constitutively active.  HPK1, 
MST1, MST2, MST3, PAK2, and MEKK1 are all STE family kinases that are 
cleaved and activated by caspases (Figure 27) [177-188].  This supports the 
notion of caspase cleavage activating NIK and subsequent downstream 
signaling. 
 
Despite its well-established role as an initiator of apoptosis, multiple studies have 
identified Caspase-8 as an activator of NF-κB [173, 189, 190].  Two of these 
studies identified a physical interaction between Caspase-8 and NIK, and went 
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on to show that NF-κB activation by Caspase-8 required NIK.  Through a co-
immunoprecipitation experiment in 293T cells, we also confirmed that NIK and 
Caspase-8 are found in together in a protein complex (Figure 28).  Interestingly, 
both Caspase-8 and NIK-deficient human patients have been described, and 
both manifest as a primary immunodeficiency with substantially impaired 
lymphocyte and Natural Killer (NK) cell function [170, 191].  Basic studies of 
Caspase-8 and NIK deficient cells support these observations, indicating that the 
impaired immunity seen in these patients results from defective activation of NF-
κB [124, 192-194]. 
 
  
87 
 
 
 
Figure 24. Caspase-8 is sufficient to induce cleavage of NIK, resulting in a 
55 kD fragment of the kinase domain.  Transfection experiment in 293T cells 
demonstrating that caspase-8 activity is sufficient to induce the cleavage of NIK, 
resulting in a 55 kD fragment of the kinase domain.  CrmA, a protein isolated 
from smallpox, is a caspase inhibitor that preferentially inhibits Caspase-8 and 
Caspase-1.  The red asterisk indicates FL NIK, while the red arrowhead points to 
the 55 kD fragment of the kinase domain. 
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Figure 25. Caspase-8 is sufficient to cleave NIK in vitro.  Purified NIK protein 
was incubated in the presence activated Caspase-8, 10 uM of Q-VD-Oph (a pan-
Caspase inhibitor), or both for 1 hour.  Incubation of NIK with activated Caspase-
8 was capable of producing a 55 kD fragment of the NIK kinase domain.  The red 
asterisk indicates FL NIK, while the red arrowhead points to the 55 kD fragment 
of the kinase domain. 
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Figure 26. Decreased levels of Procaspase-8 seen at the protein level in 
schwannomas.  (A) qRT-PCR of 8 month old WT and NF2-KO primary nerve 
tissues (seven mice total, 3 WT, 4 NF2-KO).  Caspase-8 mRNA trended higher in 
NF2-KO tissues but no significant difference was seen between genotypes.  ns = 
not significant, unpaired Student’s T-test.  Error bars represent SEM.  (B) 
Western Blotting of whole lysate SDS-PAGE samples revealed a decrease in 
Procaspase-8 at the protein level in NF2-KO tissues, suggestive of possible 
Caspase-8 activation.    
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Figure 27. Diagram indicating which STE family kinases are cleaved by 
caspases.  Phylogenetic tree of STE family kinases indicating which members 
are cleaved and activated by caspases.  NIK is identified by the blue arrowhead, 
while other STE family kinases regulated by caspase cleavage are identified with 
red arrowheads.  This image has been modified from the Promega website 
(available at the URL http://www.promega.com/a/kinase/). 
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Figure 28. Caspase-8 co-immunoprecipitates with NIK in 293T cells.  Co-
Immunoprecipitation experiment in 293T cells.  FLAG-NIK (10 ug/10 cm dish) 
was co-transfected with HA-Casp8 (1 ug/10 cm dish) in 293T cells.  FLAG-NIK 
was immunoprecipitated with FLAG antibody-conjugated agarose beads and 
samples were then separated by SDS-PAGE for subsequent Western Blotting. IB 
= Immunoblot, IP = Immunoprecipitation, WCL = Whole cell lysate. 
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Bioinformatics analysis identifies clusters of Caspase-8 cleavage sites in 
NIK 
Since we established that Caspase-8 does indeed cleave NIK to generate a 55 
kD fragment of the kinase domain, we then used Bioinformatics tools to identify 
putative sites of cleavage in NIK.  To this end, we employed two different 
software programs, Cascleave 2.0 [158, 159] and SitePrediction [160].  Both 
programs utilize features that are important to known caspase cleavage motifs, 
such as amino acid preference, secondary structure, and solvent accessibility, for 
the prediction of novel motifs.  Caspases recognize and cleave scissile bonds 
featuring a P4-P3-P2-P1-P1’-P2’-P3’-P4’ motif, with the P1 residue being an 
Aspartic acid (Asp, D) or, in certain cases, a Glutamic Acid (Glu, E) residue.  
Caspase-8 prefers an P4-P1 motif matching the pattern of IETD, but it is 
important to note that all caspases possess overlapping specificities and there 
are no absolute rules governing their cleavage, save for the D or E residue in the 
P1 position [195].  Unexpectedly, the output from both software programs 
predicted clusters of N and C-terminal Caspase-8 cleavage sites that give rise to 
an approximately 55 kD fragment of the kinase domain, with each cluster 
possessing multiple sites within roughly 20 residues of one another.  Specifically, 
both programs predicted the cleavage of D291 and D308, as well as D801, 
D807, D808, and D822 (Figure 29). The D298 site was predicted by Cascleave 
2.0 but not by SitePrediction.   
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Clusters of cleavage sites have been observed in caspase substrates before, 
and their presence would likely increase the probability of a cleavage event for 
the substrate in that region of the protein [196].  We looked at the conservation of 
these cleavage sites across other mammalian species, as conservation would 
suggest that these sites may subserve some critical function in NIK biology.  In 
the N-terminal cluster, cleavage sites homologous to D308 in human NIK were 
present in chimp, macaque, rat, mouse, dog, and cow NIK (Figure 30 A).  The 
additional cleavage site corresponding to D291 in human NIK was also present in 
chimp and macaque NIK.  Virtually all residues included in and around the C-
terminal cleavage motifs were conserved in all tested species (Figure 30 B).   
 
To further characterize the regions of NIK present in our 55 kD fragment in 
murine schwannomas, we probed these samples with a peptide antibody 
targeting murine NIK 311:328 (Figure 31).  The corresponding human residue to 
murine NIK amino acid (AA) 311 is AA 309, which would represent the 
hypothesized extreme N-terminus of our 55 kD cleavage fragment.  At least two 
fragments appeared to migrate around 55 kD in the NF2-KO tissues, providing 
additional evidence that the fragments appearing in schwannomas are the result 
of cleavages occurring in the N and C-terminal Caspase-8 cleavage site clusters 
located at roughly AA 300 and 800, respectively. 
 
After mapping the location of these cleavage sites onto the structure of human 
NIK, we made the observation that cleavage at the N and C-terminus would 
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liberate NIK from all known mechanisms of negative regulation and 
destabilization (Figure 32).  In the N-terminus of NIK, a fragment at the proposed 
cleavage sites would lose the TRAF3 binding domain (approximately residues 
30-120) as well as the overwhelming majority of the negative regulatory domain 
(NRD, approximately residues 121-317) [125, 134, 197]. Recently, an Inhibitor of 
Apoptosis (IAP) binding motif was discovered in the extreme N-terminus of NIK 
that increases the c-IAP1-mediated destabilization of NIK [198].  This motif would 
also be removed by a cleavage occurring near residue 300 in the N-terminus of 
NIK.  Structural studies of deletion mutants of NIK indicate that deletions 
proximal to residues 348 would be expected to have competent NIK kinase 
function, with residues 348-377 in the N-terminus of NIK appearing to be critical 
to the kinase function of NIK [134].  In the C-terminus of NIK, IKKα 
phosphorylates NIK at residues 809, 812, and 815, constituting a negative 
feedback mechanism that destabilizes NIK and attenuates non-canonical 
signaling [199].  In this case, cleavage at residues 801, 807, and 808 would fully 
relieve the NIK fragment of IKKα-mediated negative feedback.  The NRD of NIK 
has been shown to include a cis-acting element that disrupts the association of 
NIK with IKKα [197].  Again, a fragment at the proposed sites of cleavage would 
no longer be subject to this regulation, as this cis-acting element would be lost in 
an N-terminal cleavage event. 
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Figure 29. Computational prediction of caspase-8 cleavage sites. (A) Table 
displaying the prediction of human NIK cleavage by Caspase-8 in two different 
software programs, Cascleave 2.0 and SitePrediction.  The combination of any of 
the N-terminal cleavage site cluster (D291, D298, D308) and C-terminal cleavage 
site cluster (D801, D807, D808, and D822) results in a roughly 55 kD fragment of 
the kinase domain. (B) Mapping of cleavage sites onto the structure of human 
NIK.  Abbreviations are as follows: TRAF3-B = TRAF3 binding domain, NRD = 
Negative Regulatory domain, Kinase = Kinase domain, and CTD = C-terminal 
domain. 
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Figure 30. Caspase cleavage sites on human NIK are conserved across 
mammalian species. (A and B) Multiple sequence alignment of human NIK N-
terminal cleavage cluster (A) and C-terminal cleavage cluster (B).  Note that the 
cleavage site corresponding to human NIK residue D308 is conserved across all 
species, while all the cleavage sites in the C-terminal cleavage cluster are 
conserved.  Blue highlighting indicates the cleaved Aspartic Acid residue, while 
yellow highlighting indicates the eight amino acid caspase cleavage motif.  
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Figure 31. Further characterization of the 55 kilodalton fragment of the NIK 
kinase domain in murine schwannomas using a peptide antibody targeting 
internal NIK residues.  Whole lysate SDS-PAGE Western Blot of primary 
murine Trigeminal nerve tissue.  A custom antibody targeting a peptide 
corresponding to residues 311:328 of murine NIK was used.  Residue 311 in 
murine NIK corresponds to residue 309 in human NIK.  The antibody detected at 
least two fragments ~55 kD in NF2-KO mice.  All tissues are derived from eight 
month old mice.  The red asterisk indicates FL NIK, while the red arrowhead 
points to the 55 kD fragment of the kinase domain. 
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Figure 32. Caspase-8 cleavage of NIK renders the resulting kinase fragment 
resistant to known mechanisms of regulation of wild type NIK. Caspase-8 
cleavage sites mapped onto the structure of human NIK.  The c-IAP2/MALT1 
fusion protein cleavage site is also mapped onto the structure of NIK to 
demonstrate the location of another known cleavage site giving rise to a 
proteome-resistant fragment of NIK lacking the N-terminal TRAF3 binding 
domain.  Loss of the IAP binding motif in the N-terminus would render NIK more 
resistant to c-IAP1-mediated destabilization.  IKKα phosphorylation sites are 
included since they also are known to regulate NIK stability.  The phosphorylation 
of these sites by IKKα serves as a negative feedback loop, destabilizing NIK.  
Finally, loss of the NRD would remove a cis-acting element previously identified 
to disrupt NIK’s association with IKKα. Cleavage at the proposed sites would give 
rise to a fragment of the NIK kinase domain absent any known negative 
regulatory region present in NIK.  Abbreviations are as follows: TRAF3-B = 
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TRAF3 binding domain, NRD = Negative Regulatory domain, Kinase = Kinase 
domain, and CTD = C-terminal domain. 
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p55 NIK demonstrates increased protein stability and activates NF-κB 
To test the hypothesis that cleavages in the N and C-terminal clusters result in 
enhanced NIK stability, we generated a construct encoding residues 309-801 
NIK and transfected this construct or one encoding FL NIK into 293T cells.  We 
then pulsed cells in Cyloheximide (CHX), a protein translation inhibitor, for time 
points up to 24 hours.  The inhibition of protein translation enables us to view NIK 
protein levels purely as a function of protein degradation.  The first observation 
we made was that 309-801 NIK does indeed migrate at 55 kD, as predicted 
(Figure 33).  We also noticed increased basal stability over FL NIK.  By four 
hours of incubation with CHX, FL NIK levels had substantially decreased, and 
went on to decrease more at the ten and 24 hour time points.  309-801 NIK 
protein levels, however, did not appear to significantly change over the course of 
24 hours.  These data indicate that 309-801 NIK encodes a 55 kD fragment of 
the kinase domain with a remarkable increase in stability at the protein level 
when compared to FL NIK. 
 
Previous studies utilizing fragments of the NIK kinase domain suggest that a 
fragment encoding AA 309-801 of NIK would retain strong kinase activity toward 
IKKα, as a smaller fragment comprised of AA 329-667 was sufficient to 
phosphorylate IKKα in vitro [134].  In fact, their data demonstrates that fragments 
of 329-667 NIK and 329-747 both possess increased kinase activity toward IKKα 
compared to FL NIK, which is consistent with our reasoning outlined above.  To 
confirm that the 309-801 NIK fragment does activate downstream NF-κB 
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signaling, we transfected the 309-801 NIK construct into 293T cells.  309-801 
NIK, along with FL NIK, was sufficient to activate canonical NF-κB as measured 
by induction of phospho-S536 RELA, an IKKβ dependent site [200], and an 
increase in RELB (Figure 34A).  Both constructs also activated non-canonical 
signaling, indicated by the processing of p100 to p52.  To further assess 
canonical pathway activation, we transfected constructs into 293T cells that have 
stably integrated a consensus NF-κB responsive promoter upstream of a GFP 
reporter.  Both FL NIK and 309-801 NIK robustly activated GFP expression 
(Figure 34B).  Finally, we also validated an interaction of 309-801 NIK with IKKα 
through a co-immunoprecipitation experiment in 293T cells (Figure 35).   
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Figure 33. 309-801 NIK demonstrates increased stability over FL NIK. 
Transfection of 293Ts with the indicated plasmids.  Cycloheximide, a protein 
translation inhibitor, was added to cell culture medium and the protein levels of 
FL NIK or 309-801 NIK were monitored over a time course (labeled numbers 
above blots are hour time points).  The addition of Cycloheximide allows for the 
observation of differences in rates of protein degradation.  309-801 NIK is 
significantly more stable than FL NIK, owing to the lack of negative regulatory 
regions present in the wild type protein. 
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Figure 34. 309-801 NIK is sufficient to activate canonical and non-canonical 
NF-κB signaling. (A) Transfection of 293T cells with the indicated plasmids.  
The S536 phosphorylation of RELA and accumulation of RELB are indicative of 
activation of the canonical arm of NF-κB, while processing of p100 to p52 
demonstrate activation of the non-canonical arm of NF-κB. (B) Transfection of 
Cignal-293T cells possessing an NF-κB responsive promoter upstream of a GFP 
reporter.  FL NIK and 309-801 NIK robustly transactivate canonical NF-κB gene 
expression.  FL NIK = Full Length NIK, KD NIK = Kinase Dead NIK.  **** = P < 
.0001; ANOVA with Bonferonni post-hoc analysis.  Error bars represent SEM. 
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Figure 35. 309-801 NIK co-immunoprecipitates with IKKα in 293T cells. Co-
Immunoprecipitation experiment in 293T cells.  FLAG-IKKα (8 ug/10 cm dish) 
was co-transfected with Myc-FL NIK/Myc 309-801 NIK (3 ug/10 cm dish) in 293T 
cells.  FLAG-IKKα was immunoprecipitated with FLAG antibody-conjugated 
agarose beads and samples were then separated by SDS-PAGE and proteins 
detected through Western Blotting.  IB = Immunoblot, IP = Immunoprecipitation, 
WCL = Whole cell lysate. 
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NIK signaling regulates Schwann cell function and gene expression 
NF2-deficient cell types have previously been described to demonstrate 
abnormalities in cell proliferation, survival, and adhesion [50, 54, 201, 202].  Now 
that we identified 309-801 NIK as a kinase-competent fragment of NIK with 
enhanced stability, we examined what functional effects it has on primary 
Schwann cells.  We first confirmed that, in our culture conditions, passage one 
(P1) murine Schwann Cells are a homogenous population of mature S100+ 
Schwann cells (Figure 36A). We then transduced P1 Schwann cells with a 
Lentivirus stably inserting either an IRES-EGFP control or 309-801 NIK IRES-
EGFP cassette.  To observe for differences in cell cycle progression into or 
through S-phase, we pulsed both populations with the Thymidine analog EdU.  
Quantitation of Immunofluorescence staining revealed over a two-fold increase in 
EdU-positive nuclei in 309-801 NIK transduced Schwann cells, suggestive of an 
increase in cell proliferation (Figure 36B and C).  To address this question a 
different way, we performed manual cell counting of both genotypes three days 
after initial seeding.  This experiment revealed nearly a 1.5 fold increase in 
overall cell number in the 309-801 NIK transduced cells (Figure 36D).  We next 
assessed 309-801 NIK transduced Schwann Cells for an increase in survival in 
response to growth factor starvation.  After two days in starve media, nearly 50% 
of the 309-801 NIK transduced cells were still alive, whereas only 17% were alive 
in the IRES-EGFP control population (Figure 36E).  In addition to its more 
appreciated role governing cell proliferation and survival, NIK/NF-κB signaling 
has also been shown to regulate cell adhesion [131].  We tested if 309-801 NIK 
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transduced Schwann cells display increased adhesion relative to IRES-EGFP 
controls on Poly-D-Lysine/Laminin coated plates.  Using the iCelligence realtime 
cell monitoring assay, we noted a remarkable increase in cell adhesion through 
the first three hours after plating both populations of cells (Figure 36F). 
 
Having established that 309-801 NIK does increase Schwann cell proliferation, 
survival, and adhesion, we now used qRT-PCR to see if 309-801 NIK was 
sufficient to induce a gene expression profile similar to that observed in human 
and murine schwannomas.  As seen in Figure 37A, 309-801 NIK induces the 
transcription of four of the five Rel family transcription factors, all of which are 
NF-κB target genes, save for Rela.  Since previous studies suggest that NIK 
signaling may regulate overall levels of Rel family transcription factors [171, 172], 
this experiment presents strong supporting data that NIK signaling could be 
responsible the increased expression of Rel family proteins in schwannomas.   
 
We next examined the set of NF-κB target genes shown in Figure 12 to be 
increased in both human and murine schwannomas.  309-801 NIK positively 
regulated the expression of all analyzed genes, save for Ccnd1 (Figure 37B). 
Though 309-801 NIK only modestly increased the expression of Bcl2, a 2 fold or 
greater increase was seen in Birc2, Birc3, Ccnd2, Erbb2, and Met.  In fact, the 
overall levels of induction by 309-801 NIK mirror those seen in Figure 12C, with 
Birc2, Birc3, and Met increasing in expression the most in NF2-KO tissues 
relative to controls.  
107 
 
 
Figure 36. 309-801 NIK increases primary Schwann cell proliferation, 
survival, and adhesion.  (A) S100 staining of Passage one WT Schwann cells, 
confirming they are a homogenous population of mature Schwann cells in our 
culture conditions. Hoescht is a nuclear stain.  Original magnification x200. (B) 
Table quantitating EdU positive nuclei in both populations of Schwann cells.  P1 
primary Schwann cells were stably transduced with an IRES-EGFP control 
Lentivirus or 309-801 NIK IRES-EGFP Lentivirus.  Cells labeled with EdU are 
those that have progressed into or through S-phase of the cell cycle, which is 
indicator of cell cycle progression.  Over 400 cells were counted from three 
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biological replicates per genotype.  P < .0001, Fischer’s Exact test.  (C) 
Representative images of EdU Immunofluorescence experiment with IRES-
EGFP and 309-801 NIK transduced Schwann cells.  Red arrowheads point to 
EdU positive nuclei.  Original magnification x200.  (D) Cell counting experiment 
over the course of three days demonstrating a nearly 50 percent increase in the 
309-801 NIK transduced cell population.  ** = P < .01, unpaired Student’s T-test.  
(E) Cells transduced with 309-801 NIK demonstrate increased survival.  Cells 
were plated in the evening and the following morning the media was changed to 
starve media absent growth factors for 48 hours.  Over a 2.5 fold increase in cell 
survival was observed in the 309-801 NIK transduced population.  ** = P < .01, 
unpaired Student’s T-test.  In D and E, the unpaired Student’s T-test was used 
on raw cell counts to test for differences in the two populations.  For presentation 
purposes, the data were then re-scaled and plotted as seen in the Figure.  (F) 
iCelligence cell adhesion assay showing increased adhesion in 309-801 NIK 
transduced Schwann cells.  The unpaired Student’s T-test was used to test for a 
significance difference at the three hour time point.  *** = P < .001.  Error bars 
represent SEM. 
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Figure 37. 309-801 NIK induces expression of Rel family transcription 
factors and NF-κB target genes that are deregulated in human and murine 
schwannomas. (A) qRT-PCR in primary Schwann cells showing that NIK 
induces the expression of NF-κB transcription factors.  Note that with the 
exception of Rela, NIK induces the transcription of all Rel family transcription 
factors. (B) qRT-PCR experiment demonstrating that 309-801 NIK induces NF-
κB target gene expression similar to that observed in human and murine 
schwannomas.  ns = not significant, * = P < .05, ** = P < .01, *** = P < .001, 
unpaired Student’s T-test.  Each experiment included three biological replicates 
per genotype, per gene tested. Error bars represent SEM. 
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Evidence of persistent NIK signaling in schwannomas 
NIK has previously been shown to direct its own expression, as well as its 
negative regulators TRAF2 and TRAF3 [203-205].  We demonstrate that NIK 
strongly induces the NF-κB target genes Birc2 and Birc3, which encode c-IAP1 
and c-IAP2, the other two members of the four-part E3 complex that degrades 
NIK (Figure 37B).  qRT-PCR of primary murine nerve tissues demonstrated that 
the genes encoding NIK, TRAF2, and TRAF3 are also overexpressed in NF2-KO 
tissues (Figure 38).  Thus, all four genes encoding the negative regulatory 
complex of NIK, as well as NIK itself, are found to be overexpressed in 
schwannomas.  From these results we conclude that there appears to be 
persistent NIK signaling present in schwannomas that is no longer subject to 
negative regulation by the E3 complex comprised of TRAF2, TRAF3, and c-
IAP1/2.   
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Figure 38. The genes encoding NIK, TRAF2, and TRAF3 are overexpressed 
in murine schwannomas. (A) qRT-PCR of Map3k14, Traf2, and Traf3 in 
primary nerve tissues derived from eight month old WT and NF2-KO mice.  The 
experiments testing Traf2 and Traf3 included three WT and four NF2-KO mice, 
while the experiment testing Map3k14 included five WT and five NF2-KO mice.  
ns = not significant, * = P < .05; unpaired Student’s T test.  Error bars represent 
SEM. 
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DISCUSSION 
 
In order to identify pathways deregulated in human schwannomas, we completed 
an unbiased genomics study of published microarray data.  Through our 
analysis, we discovered activation of the NF-κB signaling pathway, with members 
of the signaling pathway and target genes seen at increased levels in 
schwannomas.  We then validated these observations in both human tumors and 
our novel mouse model of NF2, described in Chapter One.  As we examined 
these tumors for proteins that could possibly explain the apparent chronic 
activation NF-κB, we discovered that the tumors had accumulated NIK, as well 
as fragments of the NIK kinase domain.  By combining bioinformatics and 
biochemical studies to support our observations, we characterized N and C-
terminal clusters of Caspase-8 cleavage sites in NIK that give rise to roughly 55 
kD fragments of the kinase domain that are absent any known NIK regulatory 
domains.  Importantly, the single genetic manipulation of transducing primary, 
untransformed Schwann cells with an expression cassette encoding this 55 kD 
fragment of the kinase domain was sufficient to induce a transcriptional profile 
that is strikingly similar to those we identified in both human and murine 
schwannomas. 
 
Though we have identified a number of genes regulated by NIK/NF-κB in 
schwannomas, of special interest are the receptor tyrosine kinases ERBB2 and 
MET.  Both ERBB2 and MET have previously been identified as oncogenes and 
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drivers of cancer [206-209].  ERBB2 signaling is critical for Schwann cell 
development, proliferation, and survival, and its hyperactivation is believed to be 
a contributor to schwannoma formation [165, 210, 211].  Indeed, the ErbB family 
of receptors is viewed as a possible therapeutic target for schwannomas, with 
clinical trials currently in progress [212].  MET receptor expression has been 
shown to regulate schwannoma cell proliferation in vitro and, additionally, has 
been implicated in the angiogenesis observed in vestibular schwannomas [167].  
The identification of NIK as the putative driver behind the expression of both 
ERBB2 and MET has tremendous implications for therapeutic strategies to treat 
these tumors, as it provides an additional approach to preventing the increased 
expression and activation of these oncogenes in schwannomas.  
 
Through our studies in Schwann cells, we demonstrated that persistent NIK 
signaling is sufficient to explain the much of the NF-κB activation that we 
observed in schwannomas.  The single exception is RELA, whose expression is 
not induced by 309-801 NIK in Schwann cells but is increased at the RNA and 
protein level in schwannomas.  From this result we conclude that the increase in 
RELA is likely either through signaling promoted by the schwannoma 
microenvironment, or possibly a different pathway under control of NF2.  Since 
RELA is the only Rel protein that is not encoded by a known NF-κB target gene, 
it makes sense that NIK activation in Schwann cells in vitro is insufficient to 
induce its expression.  Further support of NIK regulating the increase in other 
REL proteins is seen in previous studies utilizing NIK mutant and knockout mice, 
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which have decreased levels of p100, p52, p50, RELB, and c-REL [171, 172].  
One of these studies found no difference in RELA levels [172], while another did 
see a decrease in RELA [171].  Thus, there exists some conflicting data over 
whether NIK does regulate levels of RELA, and, if so, through what pathway, 
since Rela is not a known NF-κB target. 
 
Schwann cells possess some unique characteristics among terminally 
differentiated cell types, especially in the context of nerve repair.  In response to 
nerve injury, Schwann cells drive the process of Wallerian degeneration. 
Wallerian degeneration is a physiologic process preceding peripheral nerve 
regeneration where the axon distal to the site of injury is degenerated. In this 
process, Schwann cells de-differentiate and re-enter the cell cycle [213, 214].  
Further, they increase TLR expression, become phagocytic, and release 
inflammatory mediators like IL-6 and MCP-1 to attract inflammatory cells to the 
site of injury [215-219].  Schwannomas appear to share many features of 
Schwann cells undergoing Wallerian degeneration.  Studies have indicated that 
schwannomas resemble embryonic Schwann cell lineages at the molecular level, 
indicating de-differentiation [152, 153].  NF2-null cells are also deficient in the 
ability to growth arrest, implicating deregulation of their cell cycle [54, 201].  We 
also have data demonstrating murine schwannomas overexpress TLRs, IL-6, 
and MCP-1 (data not shown).   
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Interestingly, NIK/NF-κB activation is sufficient to explain aspects of the 
phenotypes seen in both schwannomas and Wallerian degeneration.  Our data in 
primary Schwann cells demonstrate that NF-κB activation through NIK 
upregulates the expression of genes known to promote cell proliferation and 
survival.  One study identified Met to be overexpressed in regenerating nerves 
when compared to naïve nerve samples [220].  We provide clear evidence of Met 
overexpression in schwannomas, and, further, that NIK is sufficient to induce its 
expression in primary Schwann cells.  Additionally, a number of studies implicate 
NF-κB as a crucial regulator of both Schwann cell differentiation and myelination 
[68, 150, 151, 221].  The strongest support for this relationship comes from a 
study using transgenic mice expressing a non-phosphorylatable mutant of IκBα, 
which showed a direct role for NF-κB in nerve regeneration and re-myelination 
[222].  In the regenerating nerve, Schwann cells must transiently suppress the 
genes involved in myelination and then, later in the repair process, markedly 
upregulate their expression [223].  A similar process of temporal modulation of 
myelination gene expression is seen in the developing nerve, which significantly 
upregulates myelinating gene expression until adulthood, where steady-state 
expression is achieved [60].  Though clearly this relationship between NF-κB, 
Wallerian degeneration, and schwannomas is speculative, it does provide a 
compelling explanation for the similar phenotypes observed in both the 
physiologic (Wallerian degeneration) and pathologic (schwannoma) Schwann cell 
states.   
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Recently, a surprising relationship was observed between patients taking aspirin 
and VS growth.  In a retrospective study, the authors noted that a substantial 
fraction of those who took aspirin did not experience an increase in VS size 
(Odds Ratio: .5, Confidence interval: .29-85) [224].  In a follow up study, the 
same group showed that non-steroidal anti-inflammatory drugs (NSAIDs) had a 
cytostatic effect on VS in vitro, and that COX-2 expression was elevated in VS 
samples compared to normal nerve[225].  An independent group has noted a 
correlation between COX-2 expression and VS growth rate [226].  Though 
NSAIDs are widely-appreciated to mediate their effects by knocking down COX-2 
function, they are also known to inhibit NF-κB activity at doses attainable in 
human patients [227].  Further, COX-2, encoded by the PTSG2 gene, is a well-
established NF-κB target [228-230].  Thus, it is possible that the cytostatic effects 
observed in these studies are due inhibition of NF-κB activation.  The observation 
of increased COX-2 levels also supports our hypothesis of aberrant NF-κB 
activation driving oncogenic signaling in schwannomas.   
 
Our data indicates that schwannomas exhibit a simultaneous increase in the 
mRNA of the gene encoding NIK as well as all four genes encoding the E3 
complex required to degrade NIK.  All five genes have been described to be 
induced by either NIK or NF-κB [203-205, 231].  However, one would expect an 
increase in the expression of the E3 complex to negatively regulate FL NIK levels 
and, as a result, attenuate the increased levels of NIK mRNA.  The presence of a 
stabilized, proteasome-resistant fragment of the NIK kinase domain provides a 
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cogent explanation for these apparently antagonistic molecular states.  p55 NIK, 
lacking a TRAF3 binding domain, is no longer recognizable by the E3 complex 
targeting it for degradation.  Thus, p55 NIK is free to activate downstream 
canonical and non-canonical signaling and its presence in NF2-KO tissues is 
sufficient to explain the chronic NF-κB activation observed in schwannomas, with 
persistent upregulation of genes encoding Rel family proteins, IκB proteins, and 
NF-κB targets (Figure 39).   
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Figure 39. Schematic representation of hypothesized persistent NIK 
signaling present in schwannomas.  NIK induces the expression of its 
negative regulators TRAF2, TRAF3, and c-IAP1/2.  This serves as a negative 
feedback mechanism to prevent sustained activation of NIK.  p55 NIK, however, 
no longer possesses a TRAF3 binding domain, and thus continues to drive 
downstream NF-κB signaling since it is no longer degraded by the proteasome.   
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It is plausible that an increase in stability is not the only gain in function for p55 
NIK.  Previous studies using fragments of the NIK kinase domain indicate similar 
truncations result in a remarkable increase in kinase activity toward IKKα when 
compared to FL NIK [134].  There are at least two possible explanations for this.  
First, the loss of the C-terminal IKKα phosphorylation sites would prevent the 
destabilization mediated by IKKα phosphorylation [199].  However, since this was 
an in vitro kinase assay performed in the absence of protein degradation 
machinery, this explanation is less likely to be the case.  An alternate explanation 
comes from the knowledge that NIK forms dimers and transautophoshorylates 
itself as it initiates downstream signaling through IKKα [232].  The NRD of NIK is 
known to negatively regulate NIK signaling by interfering with NIK’s interaction 
with IKKα through binding a region in the C-terminus of NIK, where IKKα also 
binds[197, 232].  Though this regulation would be expected to be present in cis, 
since NIK dimerizes to activate IKKα one would also expect this regulation to be 
relevant in trans as well.  p55 NIK, however, lacks both the NRD as well as a 
portion of its C-terminus.  Thus, p55 NIK no longer possesses the NRD that 
binds to the C-terminus, but it is also possible that p55 NIK can no longer be 
targeted by the NRD present in other FL NIK molecules because of its truncated 
C-terminus.  If this is indeed the case, p55 NIK would no longer exert a negative 
regulatory influence on itself or other NIK molecules, but it would also be 
impervious to the trans regulation imparted by the NRD in other NIK molecules.  
Though we did not work up this aspect of p55 NIK and rather focused on protein 
stability, support for the hypothesized increase in activity toward IKKα is seen in 
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Figure 34A, where transfection of 309-801 NIK results in increased processing 
of p100 to p52 when compared to FL NIK.   
 
To our knowledge, there is no known link between NF2 and caspase activity.  
Thus, how direct the relationship is between loss of NF2 and altered caspase 
function in schwannomas is unclear.  PAK1, which is negatively regulated by 
NF2, is known to phosphorylate and activate Caspase-1 [233].  Additionally, 
there are other examples of PAK family proteins interacting with caspases [234-
236].  It is possible that NF2 regulates caspase function through interactions with 
PAK proteins.  The negative regulation of PAK activation by NF2 prevents PAK 
localization to focal adhesions, where Caspase-8 has also been found to localize 
and enhance tumor cell migration [53, 237].  Importantly, PAK1 is also known to 
activate NF-κB signaling through phosphorylation of NIK, thereby supporting the 
notion of PAK proteins linking NF2, caspases, and NIK in a protein complex [238, 
239].  Though we demonstrate that Caspase-8 is sufficient to induce cleavage of 
NIK and the resulting p55 fragment of the kinase domain, we do not claim that it 
is the only caspase capable of cleaving NIK.  Caspases possess overlapping 
substrate specificities such that protein localization as well as protein levels also 
likely dictate cleavage events, in addition to the preferred motifs within a 
substrate [195].   
 
While these studies have tremendous relevance to schwannoma and Schwann 
cell biology, the identification of caspase-regulated NIK/NF-κB signaling in 
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schwannomas is also a significant contribution to basic caspase and NF-κB 
biology.  The conservation of N and C-terminal cleavage sites in NIK across 
species suggests that these sites may be important sites of NIK regulation 
(Figure 30).  Since being first identified in 2000, caspase activation of NF-κB 
remains poorly understood [173, 189].  Our studies provide a possible 
explanation of this event through cleavage of NIK rendering a fragment of the 
NIK kinase domain that is free to promote downstream NF-κB signaling 
independent of its normal mode(s) of regulation.  They also provide an 
explanation for the interesting similarities seen between Caspase-8 and NIK-
deficient patient phenotypes, as well as the abnormalities observed in isolated 
cells from these patients.   
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FUTURE DIRECTIONS 
 
There are many fascinating directions emanating from the studies described in 
this manuscript.  Of chief interest to our group is the determination if NIK 
signaling is necessary and sufficient for the development of schwannomas.  We 
are currently approaching this question by conducting two rigorous in vivo proof 
of concept experiments.  First, we seek to address the question of whether NIK 
signaling is necessary for NF2-deficient schwannoma formation by intercrossing 
our NF2-KO conditional knockout mouse with a constitutive NIK knockout (NIK-
KO) mouse.  NIK-KO mice are viable but do have lymphoid tissue abnormalities 
and display poor antibody responses [124].  We will examine these mice to see if 
loss of NIK signaling rescues NF2-KO mice from the tumor phenotype described 
in Chapter One.  To test whether NIK activation in Schwann cells is sufficient to 
induce schwannoma formation, we again turn to an in vivo system.  We are 
working with SAGE labs in St. Louis to generate injectable Crispr mRNA 
encoding a donor for a conditional knock-in of 309-801 NIK into the ROSA locus.  
This donor also includes an EGFP reporter, and the cassette is under control of 
the robust CAG promoter.  Thus, when intercrossing the resulting transgenic 
mouse with a tissue specific Cre recombinase mouse, such as Postn-Cre, we 
can conditionally overexpress our NIK kinase fragment specifically in the 
developing Schwann cell lineages.  We can then characterize this mouse and 
determine if it possesses a decrease in survival and/or develops schwannomas.   
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We are also excited to study the inflammatory cytokines elaborated from 
schwannomas.  Given that NF-κB is a central regulator of cytokine and 
immunomodulatory gene expression, we would expect schwannomas to 
elaborate of number of inflammatory mediators that could possibly serve as 
autocrine and paracrine signaling factors.  We already possess some preliminary 
cytokine data through multiplex analysis of IRES-EGFP and 309-801 NIK 
transduced Schwann cell conditioned medium.  Of interest, 309-801 NIK 
transduced Schwann cells secreted 5-fold more IL-6, 18-fold more TNF-α, 149-
fold more MIP-1β (CCL4), 163-fold more RANTES (CCL5), and over 1200-fold 
more GM-CSF.  Given the paracrine signaling loop that our lab has previously 
studied between NF1-deficient Schwann cells and mast cells in the 
microenvironment, we are well-poised to further examine the interplay between 
NF2-null Schwann cells and potential cooperating inflammatory cell types [87, 
240]. 
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